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Epilepsy represents a major health burden upon society. Approximately 30% of 
patients still remain symptomatic despite therapy. Complicating development of more 
efficacious therapies is the fact that patients with similar underlying genetic causes 
display a range of phenotypes and those with similar phenotypes may display a range of 
genetic mutations. While not a current medicinal target for epilepsy, the family of 
inhibitory G-proteins appears to play an important role in this disease, as blocking their 
function in animal models increases both acute seizure susceptibility and the rate of 
spontaneous seizure development in kindling, a research model with parallels to 
epilepsy. 
 The most abundant inhibitory G-protein in the brain is Go, composing roughly 
2% of membrane bound protein. To further clarify the role of Go in epilepsy a Gnao1 
gain-of-function mouse line (RGSi/G184S) was employed. Hippocampal slices from 
Gnao1 
+/RGSi
 mice show enhanced epinephrine-mediated suppression of epileptiform 
burst firing of neurons demonstrating that Gnao1 
+/RGSi
 mice have enhanced Go 
signaling. 
The aforementioned work lead me to hypothesize that C57BL/6J Gnao1 
+/RGSi
 mice 
would be protected from kindling. In fact, the mice experience premature death, 
enhanced kindling susceptibility and over a ten-fold increase in frequency of electrical 
disturbances within their brain. C57BL/6J Gnao1 
+/RGSi
 mice also display an unexpected 
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loss of inhibitory signaling within specific brain regions. This loss may be due to changes 
in brain development as spine density on pyramidal cells within the CA1 is reduced as 
early as four weeks of age. 
Interestingly, the mutation is only lethal on the C57BL/6J background. The 
progenitor 129S1/SvImJ strain demonstrates no change in seizure susceptibility or 
viability. A genome-wide SNP analysis identified a region on chromosome 17 between 
41-70 megabases that affords protection from spontaneous lethality. Further, this region 
also reduces the rate at which mice develop seizures in response to a chemically induced 
model of epilepsy (kindling). This region was further refined to a subregion from 41-51 
megabases which was found sufficient to afford protection to kindling. Consequently, I 
have identified two genomic loci, Gnao1 and the Chr17 modifier which I term Mogs1 
(modifier of G-protein seizures), that should be examined as candidates in human 
epilepsy. Additionally, future use of this model should prove informative in assessing the 




Chapter 1  
Introduction 
Statement of purpose 
The goal of this thesis is to improve our understanding of the role of G-protein 
coupled receptors (GPCRs), a major target of current medications for other diseases, in 
convulsive epilepsy. My thesis will focus on a highly abundant protein within the brain, 
Go, that is downstream of many GPCRs, and dissect its role in controlling neuronal 
excitability. 
This introduction will start with a historical overview of epilepsy and background 
on the traditional focus of ion channels in disease pathology. The limitations upon current 
therapies will then be highlighted followed by support for the potential of novel 
therapeutics targeting GPCR signaling. Details of GPCR signaling will then be discussed. 
This comprehensive background will then be leveraged to outline the approach I 
employed to achieve the goal of my thesis. 
History and health burden of epilepsy 
Epilepsy is one of the most common neurological disorders and is associated with 
a large societal burden. Epilepsy affects approximately 0.7% of the population (Hirtz et 
al. 2007) with current treatments leaving roughly one-third of patients without relief 
(Organization 2012). Epilepsy is defined as recurrent spontaneously occurring seizures. 
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Seizures may involve involuntary body movements of all or part of the body and 
consciousness can be lost during these periods. Because of the potential to interfere with 
daily activities, epilepsy dramatically reduces the quality of life of those afflicted. Life 
expectancy is reduced by 18 years and patients are at greater risk of developing 
depression or a panic disorder (de Boer et al. 2008). 
The refractory nature of this disease may be, in part, due to two major factors. The 
first factor is the common focus of current therapies on modulating ion channels. The 
second factor is that many different rare genetic mutations likely play an important role in 
epilepsy (Michelucci et al. 2012). For about 30% of patients (Michelucci et al. 2012) the 
specific genes affected are not known. Further, even in patients with known genetic 
causes, the severity of their disease and the response to treatment are modulated by 
interactions with their genetic background (Loscher et al. 2009).  
How the brain communicates 
To understand how large networks of neurons fire in unison to create a seizure, 
we must first understand the basic principles that modulate firing of an individual neuron. 
Excitatory and inhibitory signals converge on the axon initial segment (AIS) of a neuron. 
This region acts as a gate between the cell body and the axon (Mantegazza & Catterall 
2012). A variety of ion channels in the region integrate the signals received from the 
soma leading to either the initiation of an action potential or termination of any 
depolarization further along the axon. If initiated, an action potential propagates down the 
myelinated axon via sodium channel-mediated depolarization at nodes of Ranvier 
(Mantegazza & Catterall 2012). Eventual depolarization at axon terminals promotes 
release of neurotransmitters at the synapse. These neurotransmitters then act as ligands to 
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activate various receptors on target cells, some of which are ionotropic ligand-gated ion 
channels which allow ions to flow in or out of the cell to depolarize or hyperpolarize the 
target. Neurotransmitters may also bind metabotropic G-protein coupled receptors 
(GPCRs) to induce longer term changes to cellular processes. Metabotropic receptors are 
transmembrane receptors that generate intracellular signals through generation of second 
messengers which influence a wide range of cellular processes. The major 
neurotransmitters in the brain are glutamate for excitation, gamma-amino-butyric acid 
(GABA) for inhibition, as well as acetylcholine (ACh), norepinephrine, dopamine, 
serotonin, and histamine for more specific functions within the brain. The following 
sections will discuss many of the steps in this process while highlighting literature 
relevant to epilepsy. 
Sodium Channels 
Voltage-gated sodium channels are large multi-subunit channels that play a 
critical role in the initiation and propagation of action potentials. They consist of a large 
pore forming α subunit with voltage sensing properties in the S4 segments (Mantegazza 
& Catterall 2012). During membrane depolarization the S4 segments rotate causing the 
pore to open (Mantegazza & Catterall 2012). After sustained opening, an inactivation 
gate blocks the pore, limiting the time the pore can remain open (Mantegazza & Catterall 
2012). One or two β subunits also compose a mature sodium channel where, among other 
roles, they regulate channel levels at the plasma membrane and participate in cell-cell 
adhesion(Brackenbury et al. 2008). 
 Sodium channels play a role in the pathophysiology of many types of epilepsy. 
mRNA levels of many α subunits are altered in animal models of epilepsy (Bartolomei et 
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al. 1997). Changes are also observed in human tissue taken from epileptic brains 
(Lombardo et al. 1996). Although mRNA does not always directly correlate to protein 
levels, these changes do result in functional consequences. Temporal lobe neurons taken 
from an animal model of epilepsy involving repeated electrical stimulation of the 
amygdala have larger persistent sodium channel current (INaP) than control (Blumenfeld 
et al. 2009). INaP is the result of incomplete inactivation of sodium channels after an 
action potential. This phenomenon leads to a persistent current lasting on the order of 10s 
of seconds. Typically INaP is the result of sustained opening of less than 1% of previously 
activated sodium channels, but it plays key roles in modulating repetitive firing patterns 
and with small changes can have a large impact on rhythmicity of neuronal activity, a key 
disturbance in seizures (Mantegazza & Catterall 2012). Similar changes in INaP are also 
found in resected brain tissue from human patients with temporal lobe epilepsy 
(Vreugdenhil et al. 2004). Thus increased INaP may contribute to human epilepsy in some 
cases. 
While the data above focused on gain-of-function changes, loss-of-function 
within inhibitory cells may also result in epilepsy. This is due to less inhibitory neuron 
firing leading to disinhibition of excitatory neurons for a net gain in excitation. For 
example, Dravet Syndrome can result from mutations in SCN1A, encoding the Nav1.1 
channel, which reduce sodium channel function within inhibitory neurons (Catterall et al. 
2010). This simplified view has been recently challenged by others in the field. Testing 
patient derived neurons demonstrates that SCN1A mutations initially thought to reduce 
sodium currents only within inhibitory neurons may, in fact, increase sodium currents 
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within both inhibitory and excitatory neurons through an unknown mechanism (Liu et al. 
2013). 
Potassium channels 
Among the diverse roles that potassium channels play in modulating neuronal 
excitability I will highlight their critical role in modulating the likelihood of an action 
potential leading to neurotransmitter release. The voltage-dependent potassium channel 
family is large, but all members are selective for potassium. Due to the high relative 
concentration of intracellular potassium, family members typically lead to repolarization 
of the cell and reduce neuronal excitability. Despite these similarities there are many 
differences. Each family member serves a distinct role in modulating cellular excitability 
resulting from their specific cellular localization and activity tuned to a specific 
membrane potential. This section will only discuss Kv1.1, encoded by KCNA1, in its role 
in modulating transmitter release, and mutations in KCNA1 involved in epilepsy. 
 Mutations in KCNA1 result in epilepsy through loss of function mutations. A 
T226R mutation in KCNA1 was initially discovered in patients with episodic ataxia 
(Browne et al. 1994). A subset of episodic ataxia patients with the T226R mutation 
experience epilepsy. This indicates the potential for environmental or genetic modifiers to 
play a role in modifying outcome (Eunson et al. 2000). When studied in vitro, the 
mutation reduces surface expression of the protein (Rea et al. 2002) implicating loss-of-
function as the likely mechanism. 
 A causal link between loss of Kv1.1 function and epilepsy is further supported by 
Kcna1 
-/-
 mice. These mice have spontaneous seizures accompanied by a decreased rate 
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of axonal repolarization (Smart et al. 1998). This is in concordance with data that Kv1.1 
channels predominately localize to axons and presynaptic terminals (Wang et al. 1994). 
Isolated neurons expressing T226R also exhibit enhanced release probabilities without 
enhanced intrinsic excitability (Heeroma et al. 2009). 
Calcium channels 
Voltage-dependent calcium channels are responsible for the calcium influx in 
response to cellular depolarization. The family is quite large, with various family 
members performing distinct roles. For an exhaustive review see (Catterall 2011). This 
section shall focus on N, P/Q-type calcium channels (Cav2), the activity of which is 
inhibited by GPCR signaling (Tedford & Zamponi 2006). Activation of Cav2 channels 
promotes release of neurotransmitters. Similar to sodium channels, calcium channels 
require membrane depolarization, only activate for a brief period before being 
inactivated, and require repolarization of the membrane before reopening. Despite Cav2 
channels being particularly important in regulating neurotransmitter release, few 
mutations have been reported in connection with convulsive human epilepsy.  
GABA 
GABAA receptors play a critical role in the response to GABA, the major 
inhibitory neurotransmitter in adult mammals. They are ligand-gated ion channels 
generally composed of two α, two β and one γ or δ subunits. In response to GABA 
binding, they allow influx of chloride leading to membrane hyperpolarization and a 
decreased probability of an action potential. Over 15 different mutations across all the 




To more directly assess the correlation of the mutations to epilepsy and to 
determine the mechanisms of action, transfected cell systems have been employed. 
Though the mechanisms vary, many mutations appear relevant as they have been found 
to reduce chloride conductance. Mechanisms include reduced mRNA stability, trafficking 
defects, loss of proper oligermization or altered inactivation kinetics (Ding et al. 2010; 
Frugier et al. 2007). 
Another approach to determine the impact mutations have on a disease is to 
cluster the type of mutation with the associated phenotype. If the mutation is causative 
similar mutations should result in similar syndromes. This hypothesis has been borne out 
in studies of GABAA mutations in epilepsy. Distal N terminal missense mutations are 
associated with the less severe epilepsies while proximal N terminal missense mutations 
are associated with the more severe epilepsy (Macdonald et al. 2012). 
Current therapies 
Current therapies predominantly act through modulation of ion channels. In fact, 
progress over the last several decades in treatment of epilepsy has focused on improving 
the side-effect profiles of drugs acting through the same mechanism of action (Loscher 
2002, 2011). While improving the quality of life for those whose disease is well-treated 
by current drug classes, it has continued to leave seizures in a third of patients poorly 
controlled. There are several obstacles to the successful development of new therapies for 
epilepsy which are highlighted below. 
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Complications limiting current therapies 
Genetics 
Genetics play a significant role in epilepsy with many genetic modifiers of 
epilepsy still to be discovered. Mutations in over 20 genes are known to lead to inherited 
epilepsies, examples of which were highlighted in prior sections. Risk is increased two to 
four-fold in relatives of those who suffer from idiopathic epilepsy (unknown cause) 
(Ottman et al. 1996). There is also a higher rate of idiopathic epilepsy among genetically 
identical twins compared to fraternal twins (Berkovic et al. 1998). Mendelian inheritance 
of epilepsy is however quite uncommon since many patients have no afflicted relatives 
(Ottman et al. 1996). 
There are several explanations for the genetic complexity of epilepsy. One model 
proposes epilepsy as multifactorial disease requiring multiple “hits”. In this model many 
detrimental alleles have a modest effect on their own (low penetrance). However when 
inherited together they act in an additive or synergistic fashion to promote epilepsy. In 
this model relatives would statistically be unlikely to have inherited a sufficient number 
of low penetrance alleles. A second model highlights the role of de novo mutations, the 
significance of which is already well-recognized in Dravet-Syndrome where almost 70% 
of patients have de novo mutations in SCN1A (Chakravarti 2001). De novo mutations are 
often associated with severe juvenile epilepsies whereby the severity of the phenotype 
generally prevents transmission of the mutation to subsequent generations. 
A major limiting factor in elucidating the genetics of epilepsy stems from the fact 
that there is not a one-to-one correspondence between phenotype and genotype. Many 
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syndromes can be caused by either complex inheritance or high penetrance genetic 
mechanisms which limits correlation of phenotype to genotype. Even in clearly inherited 
epilepsies, mutant alleles in a variety of genes or different mutant alleles of the same gene 
can lead to the same syndrome (Ottman & Risch 2012). 
 Complex genetic and environmental modifiers further complicate the picture as 
even the same genetic mutation does not always result in the same phenotype. This is 
exemplified by a family with an inherited mutation in SCN1A whereby various family 
members were classified with epilepsy syndromes from mild febrile seizures to severe 
temporal lobe epilepsy despite all having the same SCN1A mutation (Ottman & Risch 
2012). 
Remodeling 
In addition to the difficulty complex genetics raises, there are also complications 
due to the progressive nature of the disease. In many ways epilepsy becomes a positive 
feed-forward loop, making intervention more difficult, and the best course of action 
likely dependent upon changes that have already occurred in a patient’s brain. This is 
highlighted by three basic observations. Following seizures, the ion-channel composition 
of many neurons changes which promotes excitation, and potentially alters the 
effectiveness of current therapies (Houser et al. 2012). However, even further 
complicating matters is that the network of neurons itself changes. Death of inhibitory 
neurons leads to less inhibition of excitatory neurons (Andre et al. 2001; Dudek & Shao 
2003; Fritsch et al. 2009). A positive feed-forward loop can also develop as excitatory 
neurons sending new processes out onto other excitatory neurons in a process called 
mossy fiber sprouting (Buckmaster 2012). Lastly, new neurons can even be 
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inappropriately integrated into the network, further promoting seizures (Parent & Kron 
2012). 
GPCRs: a classic target underutilized in the treatment of epilepsy 
In the treatment of other diseases, the family of G-Protein Coupled Receptors 
(GPCRs) is a common target. Approximately 40% of prescription drugs act either 
directly or indirectly on GPCRs (Whalen et al. 2011). GPCRs reside on the plasma 
membrane where they function to convert signals from the extracellular space into 
intracellular changes. They have been a predominant focus of drug discovery efforts due 
to their distinct tissue distributions, each family member’s involvement in a limited 
subset of physiological processes, and well defined pockets for easy drugability. As of 
yet, however, they are not widely targeted in the treatment of epilepsy. 
 Both pharmacological and genetic literature support the role of GPCRs in 
modulation of seizures and the development of epilepsy in rodent models. Seizures are 
modulated by signaling through many GPCRs including: adenosine A1 (Chen et al. 
2012), galanin R2 (Lu et al. 2010), α2 adrenergic (Shouse et al. 2007), serotonin 5HT-
1(Bagdy et al. 2007; Pericic et al. 2005), and µ-opioid receptors (Grecksch et al. 2004).  
 Most interestingly, in several of these models GPCR signaling appears to impact 
the remodeling process. An experimental paradigm referred to as kindling has many 
parallels to the remodeling process in human epileptogenesis (Golarai et al. 1992; 
Morimoto et al. 2004). μ-opioid receptor null mice are more susceptible to kindling 
which supports a protective role for their action in epileptogenesis (Grecksch et al. 2004). 
Genetic models, however, can involve complex development changes. Further buttressing 
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a protective role for acute GPCR signaling, adenosine A1 activation during kindling 
suppresses the development of seizures (Li et al. 2007), indicating that activity during 
embryonic and neonatal development is not required for GPCR signaling to impact 
remodeling. 
My thesis focuses on understanding the role of GPCR signaling in epilepsy. 
Instead of focusing on a specific receptor, I will explore common downstream pathways 
of GPCRs with the goal of facilitating drug development targeting these pathways. 
Targeting downstream pathways as opposed to the GPCR itself should avoid several 
potential pitfalls that are highlighted below. 
Limitations of drugs targeting a specific GPCR 
One drawback to the use of drugs that activate GPCRs (agonists) on a chronic 
basis is the development of tolerance (Whalen et al. 2011), whereby an equivalent dose 
of a drug becomes less effective. This is a consequence of receptor phosphorylation by 
G-protein Receptor Kinases (GRKs) in response to agonist binding and subsequent 
receptor inactivation. β-arrestins may also be recruited to the receptor leading to receptor 
internalization (Whalen et al. 2011).  
A second challenge of developing drugs targeting specific GPCRs is the need to 
differentiate among structurally similar receptors that respond to a single endogenous 
ligand. For example the five muscarinic acetylcholine receptors are involved in a variety 
of cellular processes. They have a very similar binding pocket for endogenous ligand 
recognition. This has made development of subtype-specific agonists extremely 
challenging. However, without subtype-specific agonists, therapeutic utility is reduced, 
 
12 
since other family members have opposing actions or create adverse side effects (Conn et 
al. 2009). Developing therapies that act not on the receptor itself, but downstream to 
potentiate desired signaling, may eliminate these potential pitfalls. It does, however, raise 
concerns about greater side-effects due to lower specificity. 
The GABAB GPCR, a practical example of GPCR drug development limitations 
GABA, the major inhibitory neurotransmitter of the CNS, not only acts through 
the ionotropic GABAA receptor, as highlighted previously, but also acts through a single 
GPCR, the metabotropic GABAB receptor. GABAB receptors can be found both in 
presynaptic and postsynaptic locations. The major effects of GABAB activation include: 
autoreceptor inhibition of GABA release, inhibition of glutamate release, and 
hyperpolarization of cells through increased potassium conductance (Bettler et al. 2004). 
The literature supports GABAB receptors as a therapeutic target for many 
diseases. One currently used drug used is baclofen, a GABAB agonist, which serves as a 
muscle relaxant (Bettler et al. 2004). Baclofen administration can also be of assistance in 
reducing cravings in many paradigms of addiction (Bowery et al. 2002). Rats that receive 
low doses of baclofen do not self-administer heroin as often (Di Ciano & Everitt 2003; Xi 
& Stein 1999), nor do alcohol-preferring strains of mice consume as much alcohol 
(Besheer et al. 2004). Additionally, baclofen has pain relieving effects (Bowery et al. 
2002). Blockade of GABAB is also an area of interest. Antagonists are efficacious in the 
treatment of absence seizures (Vergnes et al. 1997) and improve cognitive deficits in 
animal models (Helm et al. 2005; Mondadori et al. 1996). 
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Further development of drugs modulating GABAB signaling is limited due to 
adverse side effects and the development of tolerance. Therapeutic actions occur at lower 
doses of baclofen than those required for general sedative effects (Bettler et al. 2004; 
Bowery et al. 2002). Unfortunately the difference in the dose of baclofen required for the 
beneficial effect and the sedative effect is not sufficiently large to be separable in a less 
controlled clinical setting. Tolerance also develops rapidly to baclofen's pain-relieving 
properties through an unknown mechanism (Bettler et al. 2004). Development of GABAB 
antagonists for cognitive improvements (Froestl et al. 2004) is also likely to face 
significant difficulty due side-effects, as antagonists are likely to phenocopy GABAB(1) 
knock-out mice which display a host of negative effects including increased pain 
sensitivity (Schuler et al. 2001). 
GABAB signaling occurs through only one receptor subtype, and thus selective 
agonists/antagonists with limited side-effect profiles probably cannot be developed. This 
is demonstrated by the fact that a knock out of the GABAB subunit known to bind 
GABA, GABAB(1), prevented the classical effects of baclofen administration and ablated 
radio-ligand binding of a GABAB antagonist (Schuler et al. 2001). Alternatively, if one 
could potentiate signaling of GABAB receptors to only reduce glutamate release without 
influencing other functions, this may be a novel method for the control of seizures. To 
understand how this might be possible we must understand GPCR signaling and its 
regulation in more depth. 
GPCR signaling 
GPCRs function in part through the activation of heterotrimeric G-proteins. There 
are several families of heterotrimeric G-proteins, each activates or inhibits a specific set 
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of effectors. Effectors may include enzymes or ion channels in the cell. As previously 
mentioned, activation of a number of GPCRs appears protective from seizures. The one 
commonality of these receptors is that they activate the Gi/o family of heterotrimeric G-
proteins. The relevance of this family is further highlighted by the fact that in vivo 
administration of pertussis toxin (PTX), which inactivates the Gi/o family, lowers the 
amount of excitatory stimulus required to induce seizures in rats (Ormandy & Jope 1991). 
The Gi/o family consists of several members which generally act to reduce 
neuronal excitability. In recombinant systems, all members of the Gi/o family are capable 
of reducing neurotransmitter release by suppressing the prerequisite activity of N-type 
calcium channels Family members can also activate G protein-coupled inwardly-
rectifying potassium (GIRK) channels which hyperpolarize neurons. Lastly, the family 
blocks the production of cyclic AMP, a common signaling molecule within cells that 
influences a variety of cellular events (Albert & Robillard 2002). When studied in more 
physiologically relevant systems, however, distinct roles for particular family members 
begin to emerge. In these cases, each Gi/o family member is thought to preferentially 
signal through only a subset of potential effectors, some of which are unique to the family 
member (Duan et al. 2007). 
In an attempt to understand G-protein signaling, G-protein null mice have been 
generated. Mice lacking a single inhibitory G-protein display surprisingly mild 
phenotypes. This is likely due to compensation by other family members. For example, 
despite data showing that inhibition of N-type calcium currents by GABAB is Go-
dependent under physiological conditions (Campbell et al. 1993), Go knock-out mice 
have altered kinetics, but not diminished signaling (Greif et al. 2000). Results such as 
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these clearly limit the utility of using knock-out mice to study the G-protein component 
in physiological GPCR signaling. This background raises three questions.  
1) How can one understand the role of individual family members?  
2) Further, even if one were able to enhance their inhibitory action would it have 
a beneficial effect?  
3) Lastly, how would one pharmacologically target the function of a single 
family member?  
To answer these questions we need a better appreciation for the details of the system. 
The G protein cycle 
In their inactive state, heterotrimeric G-proteins exist as trimers, consisting of an 
α, β and γ subunit with the α subunit bound to a βγ complex and guanosine diphosphate 
(GDP) (Figure 1.1 step 1). Agonist binding to a GPCR causes a conformational change 
within the GPCR which induces the G-protein to exchange GDP for guanosine 
triphosphate (GTP) (Figure 1.1 step 2). The α subunit then dissociates from the βγ 
complex and each part of the trimer may then interact with downstream effectors (Figure 
1.1 step 3). The α subunit has intrinsic GTP hydrolysis activity allowing for cleavage of 
the GTP terminal phosphate, regenerating α bound to GDP. Inactive trimer is then able to 
reform (Birnbaumer 2007a). To understand how to leverage this system in the study of 




Figure 1.1GPCR cycle 
GPCRs form complexes with heterotrimeric G-proteins in the basal state (Step 1). Upon agonist binding 
(star) GPCRs induce heterotrimeric G-proteins to exchange GDP for GTP (Step 2). The α and βγ subunits 
of the G-protein dissociate and interact with effectors (Step 3). Activation of some G-proteins is then 
terminated by a family of proteins called Regulators of G-protein Signaling (RGS). If RGS proteins are 
unable to act on the α subunit only a substantially slower self-catalyzed pathway is available to terminate 
signaling.  
 
Discovery of Regulators of G-protein Signaling (RGS) proteins 
 After the isolation of G-proteins in 1981 (Sternweis et al. 1981), a clear 
understanding emerged about the role of GTP hydrolysis in the termination of GPCR 
signals (Ross & Gilman 1980). However, it became obvious by the late 1980s and early 
1990’s that there was a discrepancy between the biochemical GTPase activity of G 
subunits and the turn-off rate of physiological signals. This was clearly documented in 
the visual system where the measured GTPase activity of transducin (Gαt) was about 10 
times slower than the turn-off of physiological responses to light (Chabre & Deterre 
1989). This was attributed in part to effects of the phosphodiestrase (Arshavsky & 
Bownds 1992) but other studies suggested the involvement of another protein (Dratz et 
al. 1987). This was also about the time when GTPase accelerating proteins (GAPs) for 
the oncogene ras were discovered (Adari et al. 1988) leading to the suggestion that there 
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might be similar GAPs for heterotrimeric G-proteins. The solution to this conundrum 
ultimately came from studies of yeast and worms. 
 Pheromone signaling in the mating of yeast (Saccharomyces cerevisiae) utilizes 
GPCRs and its study has revealed a number of key insights into G-protein signaling 
mechanisms including the role of G subunits as active signaling elements and the 
identification of RGS proteins. Haploid yeast secrete pheromones which act on GPCRs in 
yeast of the opposite mating type. This induces growth arrest and events that that promote 
fusion of the two cells for mating. Chan and Otte discovered a mutant yeast strain (sst2) 
that was supersensitive to the  factor pheromone (Chan & Otte 1982). The mutant strain 
also had a prolonged pheromone response; in continuous presence of α factor, the 
budding returned to baseline after about 4 hrs for the wild type cells but in sst2 yeast the 
effect of α factor lasted more than 6 hours after just 1 hr of exposure. This effect of the 
Sst2 protein was through direct actions on the G protein α subunit (Dietzel & Kurjan 
1987; Dohlman et al. 1995) and Sst2p is now known to represent the first member of the 
family of RGS proteins. 
Studies about the same time in the model organism Caenorhabditis elegans 
identified the gene EGL-10 which suppresses serotonin signaling through the Goa protein 
(Koelle & Horvitz 1996). This study and several others (Druey et al. 1996) defined the 
large mammalian RGS family, members of which have sequence homology to the G-
protein regulators from the model organisms. Soon thereafter, the mechanism of action 
was shown to be GAP activity on the α subunits of Gαi and Gαq G-protein family 
members (Berman et al. 1996). 
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One primary principle of RGS action on G subunits relates to specificity of 
different RGS proteins for the G subunits. Surprisingly, this specificity is relatively 
limited when examined in biochemical studies with purified RGS and G proteins. The 
Gi/o and Gq family are the primary targets and to date there have not been convincing 
demonstrations of an RGS protein acting as a GTPase Accelerating Protein (GAP) at a Gs 
protein. Figure 1.2 summarizes extensive literature on this point.  
Beyond this simple analysis of purified proteins – generally in solution – there is 
clear specificity at the level of expression in different cell types and brain regions. Also 
substantial emerging literature addresses specificity driven by complex formation 
between RGS proteins and other signaling molecules in cells – including receptors and 
several scaffold proteins such as spinophilin, R7 binding protein, and RGS-GAIP-
interacting protein. 
Combined these data indicate the potential role for RGS inhibitors as possible 
therapeutics in the modulation of GPCR signaling. It remains to be determined which 
RGS would be most useful to target. Each family member is distributed in a subset of 
tissues indicating a potential role in modulating specific disease states (Blazer & Neubig 
2009). In an attempt to identify the function of individual family members in specific 




Figure 1.2 Selectivity of RGS proteins for heterotrimeric G-proteins 
 
Drawback of individual RGS null models 
Since RGS proteins reduce GPCR signaling, Genetic deletion of an RGS should 
potentiate signaling by the G-protein upon which the RGS acts physiologically. Several 
RGS proteins for which there is quite specific tissue expression show prominent effects 
in knockouts that relate to their tissue locus (RGS1 in lymphocytes, RGS4 in SA node, 
RGS9 in eye and striatum, and RGS13 in mast cells). Unfortunately, the phenotypes of 
most RGS null mice have been surprisingly modest; many RGS null mice appearing 
normal unless careful testing is done to elicit a specific phenotype. This is probably due 
at least in part to the functional redundancy among the ~20 RGS protein family members 
(Zhong & Neubig 2001). For example, in atrial myocytes there are 7 RGS proteins with 
abundant RNA expression (Doupnik et al. 2001) and 5 of them (RGS3, 4, 10, 17, and 19) 
have broad specificity for Gi and Gq proteins.  
These findings create some concern about the utility of RGS inhibitors as 
potential therapeutics. However this concern is mollified through several lines of 
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evidence. One potential reason for the limited phenotypes is that RGS proteins may play 
a more prominent physiological role under stress or in pathological situations, thus 
requiring analysis of these animals in specific disease models. This is supported by the 
fact that RGS mRNA levels are modulated by seizures (Gold et al. 2002). Also, while 
RGS4 null mice do not display striking baseline phenotypes, in a mouse model of fragile 
X syndrome with spontaneous seizures, elimination of RGS4 function is able to 
ameliorate many of the pathophysiological phenotypes (Pacey et al. 2009). This suggests 
that RGS inhibitors should have minimal side-effects in normal individuals, but hopefully 
provide benefit in disease processes. 
Given their likely functional redundancy and the large number of different RGS 
proteins, it will be virtually impossible to undertake combinatorial knockouts of all RGS 
combinations to understand the full contribution of RGS proteins to physiological 
processes. Despite the large family size, and lack of specificity of many RGS proteins for 
specific Gα subunits how can the goal of my thesis, to identify the function of Go in vivo 
be addressed? Genetics studies in yeast will provide a solution in the form of a mutation 
that prevents the action of all RGS proteins on a particular Gα subunit. This eliminates 
the need for genetic deletion of RGS proteins and provided the ability to dissect the role 
of specific Gi/o family members due to the significant role RGS proteins play in 
negatively relating Gi/o signaling. 
Development of a novel model to study GPCR signaling 
 In 1998, Dohlman and colleagues undertook a genome-wide mutagenesis study in 
yeast to discover mutations that could phenocopy the enhanced pheromone sensitivity of 
the sst2 RGS knockout allele. The only mutation identified was a glycine to serine 
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mutation at residue 302 (RGSi) in the G subunit Gpa1 (DiBello et al. 1998). The 
mutation had no effect on nucleotide binding to or release from Gpa1. However, the RGS 
protein GAIP (a.k.a. RGS19) failed to increase GTP hydrolysis by the G302S mutant 
Gpa1.  
Subsequent biochemical studies showed that this mutation had general effects across 
multiple G and RGS proteins. In the Neubig lab, Lan et al showed that the analogous 
G184S mutations in Go and Gi1 blocked GAP activity and binding of the mutant G 
subunits to RGS4 and 7 (Lan et al. 1998). There was a >100-1000-fold reduction in the 
affinity of AlF4
-
 activated G subunits for the RGS proteins and GAP activity was 
undetectable on those mutants. Due to nature of the mutation it will be referred to 
throughout this thesis either by the amino acid substitution G184S or as RGSi for RGS 
insensitive. This mutation is in the critical switch II glycine of G subunits which occurs 
at the contact interface between RGS4 and Gi1 (PDB: 1agr) (Tesmer et al. 1997) as well 
as in other RGS proteins whose co-crystal structures with a G subunit have been solved. 
A different situation exists for RGS homology (RH) domain-containing proteins that 
don’t function primarily as GAPs for a G subunit (including the RH-domain-containing 
RhoGEFs such as LARG, PDZRhoGEF, and p115rhoGEF as well as the G protein 
coupled receptor kinase or GRK RH domains). Their interaction mode with G is quite 
different. Distinct surfaces on those RH domains bind to the G subunit and they contact 
different surfaces on the G subunit as well. In the case of these RH domains, the G184S 
mutation in switch II of the G subunit does not prevent G/RH binding or function 
(Kaur et al. 2011). 
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For all examples to date in the “classical” RGS proteins (families R4, R7, R12, and 
RZ) the RGSi mutation appears to abolish RGS binding to G and GAP function. Also, 
there has been no demonstrated effect on other functions of the G subunit including: 
binding to G, activation by receptor, or coupling to effector (Fu et al. 2004). 
Consequently, the switch II G184S mutation provides a clean molecular phenotype for 
analysis of the role of individual Gsubunits and RGS binding and/or GAP activity in 
biological function. 
Utilizing this mutation to study inhibitory G protein signaling provides three 
advantages compared to RGS null mice. First, this approach eliminates the action of all 
RGS proteins at the expressed mutant G subunit, overcoming potential functional 
redundancy. Second, the results differ from an RGS deletion in that only effects mediated 
through the RGS domain/G interaction would be affected. The role of other functional 
domains of the RGS protein (e.g. GoLoco or RhoGEF) would not be altered in these 
mutants but would be lost through genomic RGS deletion. In that sense, the G G184S 
mutants give better insights into the actions of potential drugs that would block RGS 
binding to G subunits (Neubig & Siderovski 2002); (Jin et al. 2004) (Roman et al. 
2007) than a null mouse might. Third, this approach allows one to study the role of 
specific Gi/o family members because signaling will only be potentiated through 
pathways which depend upon the mutant Gα subunit. This therefore provides a key 
method to accomplish one of my thesis goals, dissecting the role of Go within the CNS. 
To support these ideas prior in vitro work is presented. 
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Cellular studies  
In the original paper defining the yeast G184S mutation, DiBello et al. also showed a 
functional effect of the analogous mutation in mammalian Gq (DiBello et al. 1998). In 
CHO cells, transfected with the 5-HT2c receptor, serotonin increases calcium 
mobilization through Gq activation. RGS7 co-expression along with wildtype Gq reduced 
this calcium mobilization but the effect of RGS7 was abolished when a G188S mutant 
Gαq subunit was co-transfected with the RGS.  
Similarly strong effects of the G184S mutation have been defined on Gi/o functions in 
cellular systems. One commonly used tool to study inhibitory G-proteins (i.e. the Gi/o 
family) is pertussis toxin (PTX) which modifies the G to prevent activation by GPCRs. 
Protecting the G through an amino acid mutation can protect it from modification, 
making it insensitive to PTX (i.e. PTXi). Treating cells with PTX and then transfecting in 
PTXi G-proteins allows one to study their unique contribution without any endogenous 
activity due to PTX treatment. 
Clark et al used this approach to determine the effect of the G184S mutation in Go 
on opioid-induced inhibition of adenylyl cyclase (AC) in C6-mu cells – a rat glioma cell 
line stably expressing mu opioid receptors (Clark et al. 2003). PTX abolished the opioid-
dependent AC inhibition which was restored by stable expression of the PTXi-Go. Use 
of a PTXi/RGSi double mutant showed a strikingly greater inhibition of AC with 
morphine being converted from a weak partial agonist to a full agonist. Also, the full 
agonist [D-Ala2, N-MePhe4, Gly-ol]-enkephalin (DAMGO) showed a nearly 50-fold left 
shift of the dose response curve. These data were interpreted to indicate that endogenous 
RGS proteins were strongly suppressing the opioid inhibition of AC through Go and that 
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elimination of the RGS GAP on Gαo activity enhances inhibition. Subsequent studies 
extended this finding to other Gi/o family members and substantially larger effects were 
seen on the maximum AC inhibition for partial agonists while full agonists generally 
showed an increase in potency (decrease in EC50) when RGSi G subunits were 
expressed (Clark et al. 2008). 
 The RGSi mutant G subunits also profoundly change ion channel regulation in 
primary neuron cultures. Jeong and Ikeda (Jeong & Ikeda 2000) showed, using this 
approach, that norepinephrine (NE) induced inhibition of N-type calcium currents in rat 
superior cervical ganglion (SCG) is subject to regulation by RGS proteins. SCG neurons 
were transfected by intranuclear injections with PTXi Go or PTXi/RGSi Go. The 
kinetics of calcium current inhibition and recovery with a 60 sec pulse of NE were 
similar for neurons with PTXi Go compared to control neurons. PTXi/RGSi Go 
mutants showed a similar maximum NE-induced inhibition of the calcium current but the 
rate of recovery from the inhibition was greatly slowed in PTXi/RGSi mutants as 
compared to that seen in PTXi-transfected or normal cells (from 10-30 seconds in 
controls to >1-3 minutes with RGSi Go). In addition to the change in channel kinetics, 
the PTXi/RGSi mutants also resulted in an 8-fold leftward shift in the dose response 
curve for NE induced current inhibition. This was one of the first demonstrations that 
elimination of endogenous RGS function could strongly potentiate agonist function in a 
mammalian system. These actions of RGS function on calcium channels also have 
important implications for synaptic function. Chen and Lambert (Chen & Lambert 2000) 
showed that adenosine-mediated presynaptic inhibition in primary cultures of rat 
hippocampal neurons was restored to PTX-treated cells by viral transduction with PTXi 
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G-proteins (Go or Gi1). Furthermore, the recovery from adenosine-induced presynaptic 
inhibition was much slower in neurons expressing PTXi/RGSi G subunits as compared 
to those with only PTXi G protein. The time constant for recovery in the RGSi/PTXi Go 
mutant was increased to 40 sec as compared to 3 sec in the PTXi mutant Go.  
Based upon this evidence, RGS protein function, as detected by use of the RGSi 
G subunits is profound – especially in neural systems. Furthermore, these data support 
the premise that Gα function can be elucidated using an RGSi approach as RGS proteins 
are significant negative regulators of Gi/o signaling and selective blockade of their action 
on a single Gi/o family member in vivo is likely to yield profound molecular changes. 
In vivo studies 
Given the pronounced effects of the RGSi G subunit mutations in the cellular 
studies described above, the Neubig lab embarked on an effort to apply this system to in 
vivo studies in whole animals. One key consideration was how to maintain normal 
patterns and levels of expression of the mutant Gα. To address this, a knock-in strategy 
was employed where the mutant gene replaces the wild-type gene at its normal genomic 
locus. The details of how this was accomplished are outlined in previous studies (Fu et al. 
2004). In brief, the targeting construct contains the mutant codon (G184S) in exon 5 of 
Gnao1 or Gnai2 as well as a diagnostic restriction site (PvuI) that is compatible with the 
coding sequence in the mutant protein. The neo selection marker for isolating targeted 
embryonic stem (ES) cells was placed in the intron between exons 5 and 6. Preliminary 
studies (Fu et al. 2004) showed that leaving the entire neo marker intact lead to markedly 
reduced expression of the mutant Go so loxP sites flanking the neo marker were 
introduced to permit its removal after the mice were generated. Introduction of cre 
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recombinase by transfection in ES cells or by breeding mutant strains with cre-expressing 
mice left only the small single loxP site in the intron which permitted normal levels of 
G subunit expression (Fu et al. 2004). 
Gene dosage effects 
The G G184S mutation, unlike RGS null mutants, has a dominant gain-of-
function phenotype. To understand this, it is worth considering a scenario in which there 
is one G protein and one RGS protein in a system and the RGS protein suppresses the 
action of the G protein by 99% due to acceleration of turn off. In Table 1.1, the predicted 
effects of a heterozygous mutation of Gnai2 
+/G184S
 (or generically G
+/G184S
) compared 
to a RGS 
+/-
 is illustrated using a simple model based on rates of RGS-mediated G 













+/+ 1 2 91 
G
+/RGSi 46 46.5 91 
G
RGSi/RGSi 91 91 91 
Table 1.1 Predicted effects due to mutations in G subunit and RGS protein 
This table illustrates predictions of a simple model of G protein activation and deactivation and compares 
results for loss-of-function mutations in the RGS vs RGSi mutations in the G subunit. A simple 
equilibrium is assumed between an inactive G protein (G) and an active G protein G*. The total amount of 
G protein is 100. The rate of activation is constant for all situations (1 sec
-1
). The rate of deactivation is 
equal to 0.1 sec
-1
 for G protein with no RGS present and is 100 sec
-1
 with the full amount of RGS present 
(1000x stimulation). A heterozygote RGS
+/-
 is presumed to have half as much RGS so would have half the 
rate of deactivation. A heterozygous G 
+/RGSi
 is presumed to have half of its G protein behave like the 
RGS
+/+
 situation and half like the RGS
-/-
 situation. The signal strength is calculated to be equal to the 
amount of G* with 100 being full activation. 
 
 It is striking that, with these parameters, a RGS 
+/-
 shows only a 2-fold increase in 
signaling while a heterozygous G mutant (Gα 
+/RGSi
) shows a 46-fold increase. 
Homozygotes of both sorts show a strong 91-fold increase since both produce a complete 
loss of RGS function. Different parameters for the rates of activation and basal and 
stimulated deactivation would alter the magnitude of the effects but the qualitative result 
that the heterozygous RGSi G mutants give a much larger effect than the heterozygous 
RGS 
+/-
 would always be the case. Also, if there was more than one RGS acting on the 
system, a complete knock-out of a single RGS might behave more like a heterozygote 
RGS
+/-
 in this model in which only one RGS is present. Consequently, the G G184S 
mutants are expected to have much stronger phenotypes, with G
 +/RGSi
 heterozygotes 
showing clear effects perhaps approaching those of a homozygous RGSi mouse. 
RGS-regulated, Gα subtype-selective signaling in the central nervous system 
The Cornu Ammonis region 3 (CA3) of the hippocampus has one of the lowest 
seizure thresholds in the CNS due to recurrent collaterals that can mediate synchronous 
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burst firing behavior in neurons, a feature found among large populations of neurons 
during many seizures (Goldenstein et al. 2009). Synchronous firing within this region can 
be brought on experimentally by bicuculline-mediated blockade of the inhibitory GABAA 
receptors. The synchronous firing is suppressed by 2 adrenergic agonists such as 
epinephrine and UK14304, an effect mediated by 2a adrenergic receptors (Goldenstein 
et al. 2009). Gnao1
+/G184S
 RGSi mice show an 8-fold increase in epinephrine potency 
compared to wild-type mice, whereas Gnai2
+/1G84S
 RGSi mice are comparable to control 
mice. The selective potentiation of the 2a adrenergic receptor effect by the RGSi Go 
mutant suggests that this mechanism is primarily mediated by Go (at least compared to 
Gi2). While it is possible that Gi2 is involved but is not regulated by RGS proteins, the 
contrast of this result to those in serotonin signaling (see below) suggests otherwise. 
Another exciting phenotype that further supports the role of differential Gi/o 
subtype function in the CNS relates to the actions of serotonin in murine models of 
antidepressant action. In tail suspension tests, antidepressants reduce the immobility time 
of mice. The Gnai2
G184S/G184S
 mice show a spontaneous and nearly maximal reduction of 
immobility time that is reversed by a serotonin 5HT1A antagonist suggesting that 
endogenous serotonin signals sufficiently strongly in the mutants to produce an 
antidepressant-like effect. The Gnai2 
+/G184S
 mice produce an intermediate reduction of 
immobility times and, in those mice, the dose-response for the 5HT1A agonist 8-OH-
DPAT is “left-shifted” 14-fold while that for the selective-serotonin-reuptake inhibitor 
(SSRI) fluvoxamine is left-shifted 6-fold (Talbot et al. 2010). Consequently, an RGS 
protein action at Gi2 seems to be strongly suppressing the antidepressant-like actions of 
serotonin. Intriguing evidence of the specificity of this effect is seen in two observations. 
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First, norepinephrine-dependent antidepressants (e.g. amitriptyline) are not potentiated in 
the Gnai2 
+/G184S
 mutant mice. Second, there is no effect of the mutation on the 
hypothermic effect of 8-OH-DPAT. The strong effect that the RGSi Gi2 mutation has on 
5HT-dependent antidepressant-like effects with no effect on hypothermia raises the 
possibility that modulating RGS actions could greatly enhance the specificity of drug 
action – enhancing beneficial effects while not potentiating side effects.  
 
Overview of findings  
My thesis will accomplish the goals set forth at the outset of this chapter through 
the use of the unique model that the G184S mutation provides. I will outline a significant 
role for Go in modulating kindling susceptibility within a murine model. In contrast to 
prior work that only highlighted a protective role for Go in the development of seizures, 
my thesis will highlight the detrimental effects enhanced activity has in a murine model 
of epilepsy. Both pharmacological and physiological changes will demonstrate that 
enhanced Go activity induces epileptogenesis. Genetics will also be employed to identify, 
for the first time, a putative modifier region of epilepsies of GPCR signaling origin. 
In Chapter 2, I determine that mice heterozygous for the Gnao1 G184S gain-of-
function allele display phenotypes indicative of enhanced presynaptic dopamine 
autoreceptor inhibition of transmitter release. I also demonstrate that mutants experience 
spontaneous adult lethality, abnormal spontaneous electrical activity within the brain, and 
marked sensitization to an experimental model of epilepsy.  
In Chapter 3, I define a novel epilepsy modifier locus, Mogs1, on Chr 17 (41-
70Mb) which mitigates both premature death and sensitization to the experimental model 
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of epilepsy in mutant mice on the B6 background. Development of recombinant mice 
allow for the identification of the 41-51Mb subregion of Mogs1 as sufficient to afford 
protection.  
In Chapter 4, I demonstrate that the Gnao1 G184S mutation reduces GIRK action 
among three GPCRs known to modulate seizure and/or kindling susceptibility. Further, I 
confirm that these findings are not due to a loss of Go function or disruption of 




Chapter 2  
Initial characterization of Gnao1 
+/RGSi
 mice reveals a pro-seizure 
phenotype 
Summary 
Many physiological processes, including those involved in epilepsy, are 
modulated by the Gi/o family; however the specific family member involved is 
controversial in many cases. Here, I examine the role of one family member, Go, the most 
abundant inhibitory G-protein in the brain. A gain-of-function knock-in mutation that 
prevents termination of Go-mediated signaling by Regulators of G protein signaling 
(RGS) proteins results in enhanced Go signaling. Homozygous Gnao1
G184S/G184S
 
mutations are perinatal lethal. Heterozygotes are viable, but experience strain-dependent 
death between 15-40 weeks of age and increased frequency of interictal epileptiform 
discharges. Gnao1
+/G184S
 mice also have an increased rate of sensitization to 
pentylenetetrazol (PTZ) kindling, a model with parallels to human epileptogenesis. One 
potential mechanism for these findings would be enhanced suppression of GABA release. 
While suppression of GABA release could not be directly measured, autoreceptor 
function in another neurotransmitter system, dopamine, was assessed. A reduction in 
novelty-induced locomotion and levels of a common dopamine metabolite are indicative 
of less dopamine release, possibly through enhanced autoreceptor function. 
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 This work was the effort of many people. Kadee Luderman in the Gnegy lab was 
instrumental in planning and execution of dopamine studies. However, I physically 
performed all the dopamine experiments. The Parent lab performed all video EEG work. 
Undergraduates who contributed meaningfully to this work by doing genotyping and 




Despite epilepsy being one of the most common serious neurological disorders, 
current treatments leave roughly one third of patients without relief (Engel 1996). Many 
current therapies target ion channels. This common mechanism of action may contribute 
to the high percentage of patients that are refractory to current medication. New 
therapeutics targeting metabolic pathways might be an effective adjuvant for a portion of 
the refractory population. 
One potential new target to treat epilepsy is the family of G-Protein Coupled 
Receptors (GPCRs). Seizures can be suppressed by increased signaling through many Gi/o 
coupled receptors such as adenosine A1 (Chen et al. 2012), GAL2 (Lu et al. 2010), α2 
(Shouse et al. 2007), 5HT1A (Bagdy et al. 2007; Pericic et al. 2005), µ-opioid (Grecksch 
et al. 2004), and metabotropic glutamate (Alexander & Godwin 2006) receptors. Also, 
pretreatment of rats with pertussis toxin, which inhibits Gi/o family function, greatly 
potentiates seizure induction through pilocarpine or kainic acid administration (Ormandy 
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& Jope 1991). Further, genetic ablation or chemical inhibition of RGS4, a negative 
regulator of Gi/o and Gq signaling, reduces seizures (Chen et al. 2012; Pacey et al. 2009). 
The picture, however, is more complicated than simple protection by Gi/o family 
member activation. While increased activation or expression of the Gi/o coupled GABAB 
receptor can suppress generalized tonic-clonic seizures (Pacey et al. 2009), it can also 
lead to absence seizures (Hosford et al. 1992). This complexity may be partially 
explained by the fact that GABAB receptors activate multiple downstream effectors, 
likely including multiple Gi/o family members. Thus it is possible that specific effectors 
are preferentially involved in specific outcomes. The specific effector involved in 
GABAB-mediated protection against convulsive seizures has yet to be identified. 
Another potential pitfall in the current development of epilepsy medications is the 
use of acute seizure models in initial screening for efficacy. Acute seizure models 
(Loscher 2011) do not assess epileptogenesis (ie the maladaptive changes that occur after 
excitatory stimuli that lead to subsequent enhancement of seizure susceptibility) which is  
a process thought to occur in human epilepsy (Morimoto et al. 2004). Electrical or 
chemical kindling models (Bialer & White 2010) attempt to assess this with repeated sub-
threshold excitatory stimuli that eventually result in generalized seizures. 
Pentylenetetrazol (PTZ) is a non-competitive GABAA antagonist and a single large dose 
induces seizures by engaging the brainstem (Peterson & Albertson 1998). However, 
lower doses of PTZ, in a repeated-dose kindling protocol, preferentially activate the deep 
prepiriform cortex (Peterson & Albertson 1998). This causes remodeling that parallels 
changes in human epileptic brains such as mossy fiber sprouting within the dentate gyrus 
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(Golarai et al. 1992; Lee et al. 2012). Therefore to better assess the role of inhibitory G-
proteins in epilepsy I employed a PTZ kindling model. 
I hypothesized that Go is the major inhibitory G protein responsible for suppressing the 
development of seizures. 
The rationale includes the following observations: 
1) Gnao1 
+/G184S
 mice show enhanced epinephrine-mediated suppression of epileptiform 
bursting in hippocampal slices (Goldenstein et al. 2009) 
2) Go is the most highly expressed Gi/o family member within the brain, composing 2% of 
membrane bound protein (Birnbaumer 2007b) 
3) Go suppresses neurotransmitter release paralleling the actions of many epilepsy 
medications (Chen & Lambert 2000)  
4) Go is activated by the adenosine A1 receptor (Fu et al. 2006), the activation of which is 
protective in several seizure and epilepsy models (Masino et al. 2011); (Chen et al. 2012; 
Li et al. 2007) 
Contrary to my hypothesis, enhanced Go signaling resulted in spontaneous death 
by 15-40 weeks of age, frequent interictal epileptiform discharges (IEDs), and 
accelerated sensitization in a PTZ kindling model. Possible explanations for these 
unexpected findings represent a focus of my thesis. 
Enhanced presynaptic suppression of GABA release is one potential mechanism 
to explain the aforementioned data. While I was not able to directly assess this 
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hypothesis, the dopamine system was used as a model to study the effect of the Gnao1 
G184S
 
mutation on neurotransmitter release. 
Dopamine D2 receptors, a model of presynaptic inhibition by Go signaling 
Existing literature supports the hypothesis that Go is one of the major 
heterotrimeric G proteins to be activated by dopamine D2 autoreceptors. Gnao1 
-/-
 mice 
lack the high affinity D2 binding conformation which indicates that the majority of D2 
receptors are likely to associate with Go. Further, mice lacking both Gi1/2, or Gi1/i3 did not 
display a similar loss in high affinity binding (Jiang et al. 2001). In vitro data also 
provides functional evidence of D2 coupling to Go. In a pituitary cell culture model using 
GH4ZR7 cells, the D2 receptor inhibits calcium channel activity primarily through Go 
(Banihashemi & Albert 2002). 
Results 
Gnao1 
+/G184S mutant mice die perinatally 
Gnao1 
G184S/G184S
 mice die perinatally. Of mice surviving to weaning from N4 
heterozygote x heterozygote crosses on the 129S1/SvImJ background only 5% (2 of 41, 1 
male & 1 female) were homozygous mutants, with heterozygotes also underrepresented 
(Figure 2.1a Chi-squared χ² df(2)=16.02 p < 0.001). On the N4 B6;129S background, no 
homozygotes survived to weaning out of fifty-five offspring from heterozygote x 
heterozygote crosses and heterozygotes were underrepresented (Figure 2.1b Chi-squared 
χ² df(2)=45 p < 0.0001). Sex does not influence genotype distributions on either 
background (data not shown). To understand the loss of viability of mice carrying the 
G184S allele, timed pregnancies were performed for N7 B6 heterozygote x heterozygote 
crosses and embryos were collected. At E18.5, genotypes did not differ from the expected 
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Mendelian ratio (Figure 2.1c) indicating that the loss of viability occurred after E18.5 but 
before two weeks of age. Pregnant females were then monitored starting at E19 for birth 
of pups every 4-5 hours. There were very few viable homozygous offspring and 
heterozygotes were also under-represented (Figure 2.1d, Chi-squared χ² df(2)=8.76 p < 
0.02). Many homozygotes and some heterozygotes were found dead but there were no 
obvious anatomical abnormalities. This does not appear to be due to reduced Go 
expression as Go protein expression in the brain of heterozygotes at 8-12 weeks of age 





Figure 2.1 Gnao1 +/G184S mutant mice experience decreased perinatal viability 
Heterozygotex heterozygote crosses were performed on either the 129S1/SvImJ or C57BL/6J background 
as indicated. Viability was determined at various ages from E18.5 to weaning. a) N4 129S Gnao1 G184S 
mutant mice are under-represented at weaning (Chi-squared χ² df(2)=16.02 p < 0.001). b) No N4 B6;129S 
Gnao1 
G184S/G184S mice were observed by 2 weeks of age and heterozygotes are under-represented (Chi-
squared χ² df(2)=45 p < 0.0001). c) N7 B6 Gnao1 
G184S/G184S and Gnao1
 +/G184S mice are present at expected 
numbers at E18.5. d) Viable N7 B6 Go mutant mice are underrepresented within a few hours of birth (Chi-





Figure 2.2 Gnao1 +/G184S mice have normal Gαo protein levels 
a) Go expression in whole brain lysates from drug-naïve, B6129F1-Gnao1
 +/G184S female mice at 8-12 
weeks of age was assessed by Western blot. b) The ratio of Go immunoreactivity to that of the Tuj1 




+/G184S mice experience spontaneous death in adulthood 
Both male and female N7 B6 
heterozygotes, sired from a single N6 B6 
heterozygote male, experience lethality 
starting at ~80 days (11-12 weeks) with 
~50% dead by 25 weeks of age (Figure 2.3 
Gehan-Breslow-Wilcoxon df(1)=12.8 
p<0.001 B6 mutant vs wildtype control). 
Interestingly, there appeared to be 
heterogeneity in survival as the ~50% that survived to 25 weeks showed little further 
premature lethality.  
Gnao1
+/G184S mice have EEG abnormalities 
Figure 2.3 Gnao1+/G184S mice experience spontaneous 
death in adulthood 
N7 B6-Gnao1
 +/G184S 




To try to identify a cause of 
death, N7 B6-Gnao1 +/G184S mice 
(n=11) were observed three times per 
week for 30 weeks for changes in 
weight, grooming behavior, activity 
level and evidence of seizures. Three 
out of four male mice died during the 
observation period. No seizures were 
observed, nor were changes in weight 
or behavior in the days prior to death 
(Figure 2.4). However, subsequent IR video surveillance conducted around the clock (8 
mice for 16 weeks) revealed a spontaneous seizure in one mouse just prior to death. 
To further support seizures as a cause of death we employed video EEG on B6 
females. A representative EEG trace of all mice at one point in time is presented in 
Figure 2.5a. Mutant mice had a substantially elevated frequency of interictal epileptiform 
discharges (IEDs) (Figure 2.5b, unpaired t-test t=7.37 df=2.2, p < 0.02). The IEDs 
seemed to occur more frequently during electrographic sleep than during wakefulness. 
Frequently, they occurred in runs of 1-3 Hz, but they did not meet criteria of 
electrographic seizures due to their short duration. Tapes of mice were also observed 
during the lights-on period for behavioral signs of seizure activity, as it is possible that 
cortical electrodes would not detect localized seizure activity. During this time multiple 
potential seizures (with modified racine score above 1 & lasting > 10 seconds) were 
observed in the mutant mice, however they could not be confirmed via EEG data.  
Figure 2.4 No changes are observed in mouse behavior or 
weight prior to sudden death 
Male N7 B6 Gnao1
 +/+
 (average shown with SEM) and 
B6 Gnao1
 +/G184S mice were observed three times per 
week. Behavior, weight, and deaths were recorded 3 
times per week. No reproducible trend was observed in 
mutant mice prior to death. Three deaths were observed 





Figure 2.5 B6 Gnao1 +/G184S mice have a greater frequency of IEDs 
a) Simultaneous EEG of heterozygote (n=3) and wildtype (n=2) mice is presented at a representative time 
point. Vertical bars demark the passage of 1 second. B) Mutant B6 females experience greater than 10 fold 





+/G184S mice are sensitized to PTZ kindling  
To determine the physiological 
significance of the elevated IEDs we 
assessed susceptibility to epileptogenesis in 
mutant mice. Female B6 Gnao1+/G184S 
mutants were more sensitive to PTZ 
kindling than control (Figure 2.6a Gehan-
Breslow-Wilcoxon df(1)=5.74 p<0.02). The 
increased PTZ kindling susceptibility on the 
C57BL/6J background was independent of 
gender as males also showed sensitization 
(Figure 2.6b, Gehan-Breslow-Wilcoxon 
df(1)=6.88 p<0.01) just as was the case for 
spontaneous death.  
  
Figure 2.6 Gnao1 +/G184S mice have a strain-dependent 
reduction in time to sensitize to repeated low dose PTZ 
The time to undergo sensitization to PTZ kindling 
(see Methods for definition) was recorded. a) B6-
Gnao1
 +/G184S females sensitize more rapidly than 
littermate controls (Gehan-Breslow-Wilcoxon 
df(1)=5.74 p<0.05). b) B6-Gnao1
 +/G184S males also 
sensitize more rapidly than littermate controls 






 mice have reduced novelty-induced locomotion 
Mice were exposed to a new environment, which activates reward pathways 
leading to an increased exploratory behavior. More dopamine release is associated with 
more novelty-induced locomotion. Both male and female Gnao1 
+/G184S
 mice have 
reduced novelty induced locomotion (Figure 2.7). One potential explanation for this 
finding is that mutant mice release less dopamine due to enhancement of Go action. 






Figure 2.7 Gnao1 +/G184S mice experience less novelty-induced locomotion 
a) Male mutant mice travel less distance within the first 30 minutes of a novel environment. [n=3, p < 0.02, 
unpaired t-test t=3.636 df=5] b) Female mutants also experience a reduction in distance traveled within the 
first 30 minutes. [n=10, p < 0.01, unpaired t-test t=3.438 df=19] c) Male wildtype mice do not reach an 
equivalent baseline level of locomotion after acclimation complicating interpretation d) Female wildtype 
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Total dopamine is unaffected, but dopamine metabolites are reduced in Gnao1 
+/G184S
 mice 
In an intact animal model, alterations in many other signaling pathways may 
result in the observed reduction in novelty induced locomotion. To more directly assess 
changes in dopamine release levels of dopamine and various metabolites were measured. 
Lower release of dopamine should result in a reduction of its metabolites. This was found 
to be the case with mutant mice having a reduced amount of the dopamine metabolite 
homo-vanilic acid (HVA). (Figure 2.8). 
 
Figure 2.8 The level of HVA is reduced in Gnao1 
+/RGSi mice 
Brains of drug naïve mice were rapidly dissected 
using a brain matrix to harvest the indicated 
regions. a) Total dopamine levels were unaffected 
by mutation [n=7] b) A common metabolite of 
dopamine, HVA was decreased within the CCP of 
mutant mice [n=7]. Abbreviations are as follows - 
CCP – caudal slide of caudate putamen. RCP – 
rostral slice of caudate putamen. NAc – nucleus 
accumbens. POA – preoptic area. VTA – ventral 









 Alternative hypotheses to explain a reduction in novelty induced locomotion 
include: less downstream response to dopamine despite equivalent release or defective 
motor coordination. To rule this out in in Gnao1 
+/G184S
 mice the ability of a D1 agonist to 
stimulate locomotion was tested. Here no 
difference was detected at roughly an EC50 dose 
suggesting that response to dopamine is not 
outside of the physiological range (Figure 2.9). 
Additional testing of motor coordination on a 
rotarod did not demonstrate a significant 









 mice and controls were placed on a 
rotarod at 12RPM to assess motor function. 
Gnao1 
+/G184S
 mice have a similar baseline to 
control but slightly underperformed control with 
repeated trials. This difference however was not 




Figure 2.9 D1 function is not altered in Gnao1 
+/G184S 
mice  
Mice were acclimated to the recording chamber 
followed by a saline injection. Locomotion 
recorded following saline injection is “baseline.” 
D1 agonist was then injected and locomotion 
recorded as “stimulated.” Differences in baseline 
locomotion were compensated for by determining 
magnitude of increase in locomotion from saline. 
See “delta.” The mutant did not influence the 
ability of the D1 agonist to increase locomotion. 
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In this chapter I demonstrate that Gnao1 
+/G184S
 mutants experience spontaneous 
adult lethality, enhanced frequency of IEDs, and marked sensitization to PTZ kindling. 
This is in contrast to previous work focusing on acute inhibition of Go signaling which 
indicated a protective role for the protein. This suggests that GNAO1 should be 
considered as a potential candidate gene in human epilepsy studies as either gain or 
reduction of function appears to be detrimental. Indeed, Nakamura et al. recently found 
de novo mutations likely to cause loss-of-function or gain-of-function are associated with 
epileptic encephalopathy (Nakamura et al. 2013). 
 It was surprising that enhanced Go signaling would lead to PTZ kindling 
sensitization. Go suppresses neurotransmitter release (Campbell et al. 1993; Chen & 
Lambert 2000) and Gi/o proteins have been shown to protect against seizure activity 
(Goldenstein et al. 2009; Ormandy & Jope 1991). Given the role for Go in the inhibition 
of calcium channels, this gain-of-function mutation may mimic the paradoxical results of 
high-dose levetiracetam treatment. Levetiracetam, which is used in therapy of partial 
onset seizures, also acts on presynaptic calcium channels (Lee et al. 2009; Vogl et al. 
2012). While it has anticonvulsant effects at low doses, it can become proconvulsant at 
high doses (Shorvon 2010). 
It is also possible that developmental changes due to mutant Go are responsible for 
our observations. This is supported by the prior findings that Go activation can stimulate 
neurite outgrowth in cell culture models (He et al. 2006) and the related Gi2 G184S 
mutant alters self-renewal and differentiation in neural progenitor cells (Murai et al. 
2010). However, prior work in Gnao1 
-/-
 mice lacking functional Go has failed to identify 
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any defects in brain development (Valenzuela et al. 1997). 
Understanding the relationship between IEDs and PTZ kindling within this model 
may also provide key insights into epileptogenesis. Currently, the role of IEDs in the 
development of epilepsy is under debate. Some researchers believe that IEDs serve as a 
protective mechanism to reduce the likelihood of future ictal events (Avoli 2001). Others 
have postulated that the enhancement in interictal firing promotes mossy fiber sprouting 
and enhances development of epilepsy (Staley et al. 2011). As this debate continues, this 
mouse line should serve as a tool to validate novel anti-IED drugs and assist in the 
determination of how these novel therapeutics impact outcomes. 
The initial phenotype observed in this mouse model was sudden death and not an 
overt epilepsy syndrome. We were, however, able to observe seizures prior to death in a 
few mice with one documented on video. The Gnao1 G184S mutation also enhances 
bradycardia to muscarinic and adenosine signaling (Fu et al. 2006). One proposed 
mechanism of SUDEP is post-ictal bradycardia or hypoventilation (Surges & Sander 
2012) so a mutation in GNAO1 could exacerbate bradycardia in the setting of seizures 
which might contribute to SUDEP. Also, hypoventilation may underlie the perinatal 
lethality of the homozygous Gnao1
G184S/G184S
 mutants given the large number of non-
viable births (74%). With the combination of seizures and enhanced bradycardia, it will 
be of significant interest to determine whether humans with SUDEP might carry such a 
mutant GNAO1 allele. 
One potential mechanism behind the enhancement of Gnao1 
+/G184S
 kindling 
susceptibility is enhanced inhibition of GABA release. While this was not directly 
assessed, the dopamine system was used as a model for assessing the mutation’s effect on 
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neurotransmitter release. Here my data are in line with the hypothesis that Gnao1 
+/G184S
 
mice have reduced neurotransmitter release. Normally in response to a novel environment 
dopamine is released which promotes locomotion. Enhanced suppression of 
neurotransmitter release through D2 activity would be expected to reduce novelty-induced 
locomotion (Benoit-Marand et al. 2001). Mutants have decreased novelty-induced 
locomotion potentially indicating less dopamine release or less responsiveness to 
dopamine. This was further tested through analysis of dopamine metabolites at baseline 
which were found to be lower in mutant mice. Additionally, responsiveness to dopamine 
was assessed through direct activation of dopamine receptors known to stimulate 
locomotion. In this case the mutation had no impact on outcome. Thus, decreased 
responsiveness to dopamine and motor impairment are unlikely to be major contributing 
factors. The reduction in novelty-induced locomotion among mutants could, however, be 
due to decreased stimulus input in the novel environment. This alternative hypothesis will 
need to be tested through further experimentation. Connecting these observations to 
epilepsy, preliminary data generated by Dr. Yuan suggests that GABA release is also 
inhibited in Gnao1 
+/G184S
 mice. Figure A.3 illustrates that the mice experience both a 
lower probability and lower amplitude of spontaneous inhibitory post synaptic currents 
within the hippocampus which is indicative of presynaptic changes. Future work will 




Materials and Methods 
Generation of Gnao1 
+/G184S
 mice and perinatal viability experiments 
We previously reported (Fu et al. 2007; Fu et al. 2006) enhanced bradycardia in 
studies of ES-cell derived cardiocytes carrying a Gnao1 G184S knock-in. The tm1Rneu 
allele in those reports was generated in DE3 ES cells but never resulted in germline 
transmission. Subsequently, we generated a similar Gnao1 G184S knock-in (tm2Rneu) 
allele in the 129-steel derived ES line, CJ7. This allele is referred to as G184S or RGSi 
throughout this thesis. The mutant allele construction from a CJ7 bac library was detailed 
previously (Goldenstein et al. 2009). After germline transmission of the mutant allele, 
pure agouti offspring were crossed to a 129-steel derived mouse expressing Cre 
(129S/Sv-Tg Prm-cre 58Og/J stock # 003328 from Jackson Labs, Bar Harbor, ME) and 
tested for excision of the loxP-flanked Neo cassette which was previously found to 
reduce Go expression (Fu et al. 2007; Fu et al. 2006). Subsequent breeding on all genetic 
backgrounds was performed with a Gnao1
+/G184S
 male and Gnao1
+/+
 females with the 
exception of heterozygote x heterozygote crosses. Mice lacking the Neo cassette were 
backcrossed to the 129-steel line 129S1/SvImJ (Jackson Labs stock # 002448). After 
reaching N8, brother-sister crosses were performed. To limit the effect of genetic drift 
associated with repeated brother-sister crosses in our 129S1/SvImJ breeding we bred 
G184S carriers to female 129S1/SvImJ mice directly obtained from Jackson Labs 
roughly once after every 4 brother-sister crosses.  
To obtain mutant mice on the C57BL/6J background, the tm2Rneu allele, after 
Neo excision, was successively backcrossed onto the C57BL/6J background (Jackson 
Labs stock # 000664). 
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Perinatal viability was established through timed pregnancies testing for plugs 
every morning which, if found, were designated E0.5. Eighteen mice were used at E18.5 
and 33 at P0. 
Genotyping 
All mice had eartags inserted and tail biopsies taken prior to weaning. DNA was 
extracted from tails by an alkaline lysis method (Truett et al. 2000). The G184S allele of 
Gnao1 was identified by PCR with primers GoFlankLoxP.A CGC AGG CTC TGA GGG 
CCT AAG & GoFlankLoxP.B TGC CTC ACC TCT CCG TCT CC. Reaction conditions 
were as follows: 1µl template, 4µl 5x Promega PCR buffer, 0.4µl 10mM dNTPs, 0.4µl 
20µM GoFlankLoxP.A, 0.4µl 20µM GoFlankLoxP.B, 0.2µl Promega GoTaq and 13.6 µl 
DNase free water (Promega catalog # M3005, Madison WI). Reaction mixtures were 
denatured for 4 minutes at 95
o
C and then cycled 32 times through denaturing at 95
o
C for 
30 seconds, annealing at 64
o
C for 30 seconds, and extension at 72
o
C for 30 seconds. A 
final extension of 8 minutes at 72
o
C was then performed. The wildtype allele generates a 
181bp product and the G184S allele produces a 361bp product. 
Western blot 
Brain homogenates were collected from group housed B6129F1 female mice 8-12 
weeks of age. Mice were anesthetized by an overdose of sodium phenobarbital 
(University of Michigan Pharmacy) and the right hemisphere was collected in a 
microcentrifuge tube filled with 100ul of 0.5 mm glass beads (Next Advance, Averill 
Park, NY) and 600ul RIPA buffer. Brains were then homogenized and tissue lysed via a 
bullet blender (Next Advance) following the manufacturer’s recommended settings. 
Samples were then centrifuged at ~10,000 RCF for 10 minutes. Protein in the supernatant 
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was quantified by a BCA kit (Pierce, Rockford, IL) and diluted to 2ug/ul protein in 
Laemmli buffer (Biorad, Hercules, CA). Western blots were then performed following 
standard protocols using 10% acrylamide gels transferred to PVDF membrane (Millipore, 
Billerica, MA). Gαo antibody was provided by Dr. Thomas Gettys (Louisiana State 
University) and used at a dilution of 1:1,000. TuJ1 antibody PRB_435P (Covance, Battle 
Creek, MI) was used at 1:5,000. Goat anti rabbit-HRP (Sigma, St. Louis, MO) was used 
at 1:10,000. Chemiluminescent substrate (Pierce) was applied for 5 minutes and blots 
were visualized and analyzed using a LiCor Odyssey imager using Image Studio 1.1. 
Video EEG 
Female mutant and control mice approximately 24 weeks old were implanted with 
electrodes, given one week to recover, and monitored under video EEG as described 
previously with a sampling frequency 256 Hz, sensitivity 30 uV/mm, and low frequency, 
high frequency and notch filter settings of 1 Hz, 100 Hz and 60 Hz, respectively (Lee et 
al. 2012). Older females were chosen due to the progressive nature of epilepsy and 
because females of inbred strains generally have a lower seizure threshold, increasing the 
likelihood of detection if seizures were the cause of spontaneous death (Frankel et al. 
2001). The animals were continuously recorded for 96-206 h.  
Automated spike detection analysis gave a high proportion of false positive and 
false negative calls based on manual confirmation. Therefore the results of automated 
detection are not reported. Semi-quantitative assessment of interictal epileptiform 
discharges (IEDs) was performed. The total number of IEDs was counted during 24 
discrete and random 5 min epochs (Research Randomizer Version 3.0 retrieved on April 
29, 2013 from http://www.randomizer.org/) and presented as aggregate count of IEDs/h. 
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IEDs were defined as waveforms lasting 20-200 ms, at least 3 times the background 
activity in amplitude, disturbing the background and not better described as waveforms of 
normal sleep or wakefulness. Seizures were defined as discrete events characterized by 
appearance of continuous repetitive IEDs or rhythmic high-amplitude activity, lasting at 
least 10 s and with unequivocal evolution in frequency, morphology or distribution.  
Seizure susceptibility and epileptogenesis susceptibility 
To test susceptibility to epileptogenesis, a PTZ kindling protocol was performed 
on both male and female mice. PTZ was administered 3 times per week at 35mg/kg 
starting at 8-12 weeks of age; mice were monitored for 30 minutes for behavioral signs of 
seizures as described by (Wilczynski et al. 2008), (Grecksch et al. 2004) and (Dhir 2012). 
This dose does not typically elicit effects greater than behavioral arrest on the first dose in 
wildtype mice regardless of gender or strain (lab observation). Behavior was recorded 
and then scaled to a modified Racine scale where 0 indicates no response, 1 is behavioral 
arrest, 2 is a tail flick, twitch, or body tremble, 3 is a forepaw press, 4 is a tonic clonic 
seizure involving loss of upright posture, and 5 is wild jumping or death (Racine 1972). 
Loss of upright posture was defined as having at least one front and one rear paw off the 
cage floor. Sensitization is defined as death or having 2 sequential sessions with a score 
of 4 or greater. The number of injections for each mouse to reach a sensitized state is 
reported in a survival curve in the results section. Survival curves for time to first tail 
flick and time to first forepaw press are also presented in Appendix A. Mice that died 
between observational periods were excluded from the survival curve at the last dose for 
which they could be observed since seizure could not be confirmed as cause of death. 
These exclusions were rare (less than 5%). In females, kindling could be influenced by 
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estrus cycle. To control for this, females were group housed with mutant and wildtype 
genotypes in equal numbers in each box to obtain synchronization of estrus cycle 
(Jemiolo et al. 1986). All mice in a given box entered kindling on the same day to ensure 
that an equal number of females per genotype were started at the same point in their 
cycle. 
Novelty induced locomotion 
Mice were habituated to the testing room first thing in the morning for a minimum 
of an hour. All tests were completed in the morning due to the circadian influence on 
dopaminergic stimuli (Abarca et al. 2002). Activity was recorded for two hours by an 
automated camera and computer system in collaboration with the Murphy laboratory. 
Motor coordination and learning 
Mice were placed onto a rotarod at 12RPM and time on rotarod was scored out of 
a maximum of 300 seconds. Time spent clinging to the rotarod was excluded, similar to 
prior studies (Jacobson & Cryan 2005). 30 minutes was provided between trials. 
Metabolite analysis 
Mice were cervically dislocated and then decapitated. Brains were rapidly 
dissected on ice and placed into a 30g mouse coronal brain matrix. 1mm slices containing 
specific regions were isolated and anatomically confirmed through use of a mouse atlas. 
Wet weight of each brain region isolated was recorded for normalization. Tissues were 
suspended in 100ul 2N percholric acid and homogenized followed by a spin at max rcf in 
a bench top centrifuge for 20 mins at 4 degrees. Samples were then diluted in ISS at the 




Diluted samples were then filtered with a 0.22um pore size syringe filter and then 
injected at 300mV with 10nA sensitivity for 13 minute runs except the CP, Nac and POA 
which was run with 20nA sensitivity because the dopamine signal was being clipped. 
For quantification a standard curve with HVA, DPOAC, and dopamine in ISS was 
run at 10 & 20nA. DOPAC standards ranged from 100nM to 0.1nM. HVA standards 
ranged from 100nM to 1nM. 
D1 stimulated locomotion 
To test D1 mediated stimulation of locomotor activity mice were habituated to the 
automated activity recorder. Once mice displayed baseline locomotion within the 
chamber (no novelty induced locomotion) mice were injected with saline and recorded 
for 2 hours to quantify baseline activity. Mice were then injected with the D1 agonist 
SKF81297 and their activity measured for another two hours (Usiello et al. 2000). 
Statistical analysis 
Data were analyzed using GraphPad Prism 5.0 and GraphPad QuickCalcs (GraphPad; 
LaJolla, CA). Chi squared analysis was used to evaluate deviation from Mendelian ratios. 
Proportionality of hazards for survival curves were analyzed using SAS 9.3 (SAS 
Institute; Cary, NC). The Gehan-Breslow-Wilcoxon test was applied to survival and 
kindling data as opposed to logrank because the survival curves failed to meet the 
proportional hazard assumption required for valid application of logrank (Machin et al. 
2006). In analysis of EEG data, a parametric unpaired t-test was performed assuming 
populations with different standard deviations using Welch’s correction. Two tailed P 
values less than 0.05 were considered significant. 
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Chapter 3  
Genetics of strain-dependent lethality and kindling 
Summary 
Chapter 2 introduced the Gnao1 
+/G184S
 mouse model and identified their 
enhanced response to PTZ kindling, abnormal EEG and spontaneous death. Here I 
identify a novel Chr17 modifier region that affects both PTZ kindling and spontaneous 
death in Gnao1 
+/G184S
 mutant mice. The initial region identified spanned from 41-70Mb. 
However this was further refined through use of recombinant mice to 41-51Mb. 
Consequently, I have identified a novel genomic locus, the Chr17 modifier region, which 
we term Mogs1 (modifier of G-protein seizures), that should be examined as candidates 
in human epilepsy and sudden unexplained death in epilepsy (SUDEP). 
I designed all experiments in collaboration with my mentor Dr. Neubig. I 
instructed undergraduates on how to perform genotyping and kindling which was 
predominately completed by them. Mouse breeding and final assembly and interpretation 
of data were performed by me. The genome-wide sequencing was performed by the DNA 
sequencing core based on a design by Dr. Neubig. Past and current undergraduates who 
meaningfully contributed to this work include Kevin Kohut, Kristen Gilbert, Madeline 




The majority of epilepsy cases are not due to a known environmental cause, 
leaving genetic factors to play an important role (Michelucci et al. 2012). Rare mutations 
in ion channels (Ryan 1999), metabolic mechanisms (Suls et al. 2009), and 
neurodevelopmental pathways (Eksioglu et al. 1996) produce genetic epilepsies with 
strong Mendelian inheritance. Also, a catch-all category of “general genetic epilepsy” 
accounts for about 30% of patients (Michelucci et al. 2012) but the specific genes 
affected are not known. Indeed, most of the genes from well-defined familial epilepsies 
have been ruled out in those patients (Klassen et al. 2011). A role for more than one gene 
in individual patients (Leu et al. 2012) or modifier loci (Bergren et al. 2009; Meisler & 
Kearney 2005) has been proposed as an explanation for why the genetic basis has been 
difficult to discern. 
Beyond causation, treatment response and prognosis are also highly variable 
among patients and are probably influenced by genetic determinants. In severe myoclonic 
epilepsy of infancy (SMEI), which is caused by loss of function in the sodium channel 
SCN1A (Claes et al. 2001), patients do not respond to typical anti-epileptic treatments 
that further decrease sodium channel activity. Efficacy of treatment response in the 
general epilepsy population is also determined in part by genetic modifiers (Loscher et al. 
2009; Szoeke et al. 2006). Genetic factors also appear to contribute to the phenomenon of 
sudden unexplained death in epilepsy (SUDEP) (Sperling 2001). About 10-15% of 
SUDEP patients have mutations related to long QT syndrome that could lead to cardiac 
arrhythmias (Surges & Sander 2012) but the majority of cases remain unexplained.  
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Many labs have worked to understand the influence of genetics on modifying 
outcome in various seizure models. Loci on mouse Chr 1, 2, 3, 4, 5, and 6 have all been 
previously identified to modify seizures induced by acute Pentylenetetrazol (PTZ) 
(Ferraro et al. 1999; Legare et al. 2000). Mouse Chr 4, 15 and 8 have also been 
implicated in the Kainic Acid (KA) model (Schauwecker et al. 2004). Unfortunately due 
to the acute nature of these models, they do not provide insight into genetic modifiers of 
the remodeling process leading to many human epilepsy syndromes. Therefore better 
therapy for refractory cases relies upon a better understanding of the complex genetic 
interactions leading to epilepsy and identification of novel targets.  
Here I identify a novel Chr17 modifier region that affects both PTZ kindling and 
spontaneous death in Gnao1 
+/G184S
 mutant mice. The initial region identified spanned 
from 41-70Mb. However this was further refined through use of recombinant mice to 41-
51Mb. Consequently, we have identified two genomic loci, Gnao1 and the Chr17 
modifier which we term Mogs1 (modifier of G-protein seizures), that should be examined 




Figure 3.1 Gnao1 +/G184S mice experience strain-
dependent lethality 
a) N6 129S1/SvImJ-Gnao1 
+/G184S and N7 B6 
wildtype mice experience a relatively normal 
lifespan compared to N7 B6-Gnao1 
+/G184S
 
(Gehan-Breslow-Wilcoxon df(1)=12.8 p<0.001) 
b) N7 B6-Gnao1
 +/G184S 
mice die prematurely 
regardless of gender 
Results 
Heterozygous Gnao1
+/G184S mice experience strain-dependent spontaneous death 
In contrast to the spontaneous death in B6 
Gnao1 
+/G184S
 mice reported in Chapter 2, 
heterozygous Gnao1 
+/G184S
 on the 
129S1/SvImJ background live a relatively 
normal lifespan with 100% surviving >1 
year (Figure 3.1). The difference in 
outcome, based upon genetic background, 
suggests that a genetic approach could 
provide insights into the mechanism 
behind the Gnao1 
+/G184S
 mediated 






 +/G184S spontaneous death is modified by a region within 41-70 Mb on 
Chromosome 17 
No deaths were observed up to 47 weeks in mutant B6129SF1 (F1) mice 
regardless of their gender (n=8 per sex per genotype). Thus 129S alleles appear to 
provide a dominant protective effect against the spontaneous death phenotype of 
Gnao1
+/G184S mice or, conversely, the C57BL/6J background effect is recessive. 
To define the genetic locus underlying the strain differences, the 11 male and 7 
female N7 B6 Gnao1+/G184S mice from Figure 3.1b were split into two groups, the short-
lived group was defined as those that died prior to the survival curve leveling off at ~ 25 
weeks of age. The long-lived group included those that lived past the 25 week cutoff. 
Females were equally represented in both the short and long-lived cohorts. Males were 
skewed towards the long lived cohort, but this was not significant. The frequency and 
location of 129S alleles were compared between the short-lived and long-lived groups. 
Given the dominant effect of 129S alleles in F1 mice, we expected that a single copy of 
the 129S alleles in B6 mutant mice would be protective and therefore be found at a 
greater frequency in the long lived cohort. All mice retained 129S alleles on Chr 8 that 
are near the Gnao1 locus as expected (Figure 3.2a). The only region that preferentially 
retained 129S alleles in the long-lived cohort was on Chr17 after 39Mb through the end 
of the chromosome (Figure 3.2 a & b). The x axis labels in Figure 3.2b represent the 
locations tested where SNPs differ between 129S and C57BL/6J mice. This initial 
analysis was not sufficiently powered to statistically validate the modifier due to the 
required correction for multiple comparisons.  
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To both confirm and reduce the size of the modifier, we obtained recombinant 
mice that only maintained 129S alleles at 47Mb and 62Mb but were homozygous for B6 
alleles at 41Mb & 70Mb allowing us to roughly split the putative modifier region in half. 
In an independent experiment with these 44 mice, we tested the ability of the 41-70Mb 
subregion to afford protection, thus eliminating the need for the multiple comparison 
correction. The Chr17 129S 41-70Mb subregion protected B6-Gnao1 
+/G184S
 mice from 
spontaneous death in the independent cohort (Figure 3.2c Gehan-Breslow-Wilcoxon 






Figure 3.2 A locus on chromosome 17 modifies 
the strain-dependent lethality 
a) Whole genome SNP analysis was done and 
retained 129S alleles were assessed. Plots 
show the percentage of the B6 Gnao1 
+/G184S
 
mice carrying 129S alleles at a particular 
location in the genome. Those that lived past 
25 weeks of age are in red and those that died 
prior are in black. b) Only one region on Chr 
17 showed preferential retention of 129S 
alleles in the population that lived past 25 
weeks of age. c) In an independent cohort we 
tested for the ability of the first half of this 
putative modifier region to enhance viability of 
B6-Gnao1 
+/G184S mice. Those mice retaining 
129S alleles at both 47Mb and 62Mb (but 
homozygous B6 at 41Mb & 70Mb) on Chr 17 
showed increased survival (Gehan-Breslow-




Figure 3.3 Gnao1 +/G184S mice have a strain-dependent 
reduction in time to sensitize to repeated low dose PTZ 
The time to undergo sensitization to PTZ kindling (see 
Methods for definition) was recorded. a) N7 129S-
Gnao1 
+/G184S
 female mice sensitize in response to PTZ 
similar to control. b) B6-Gnao1 
+/G184S
 females sensitize 
more rapidly than littermate controls (Gehan-Breslow-
Wilcoxon df(1)=5.74 p<0.05). 
Heterozygous Gnao1 
+/G184S mice also have a strain-dependent sensitization to PTZ 
kindling  
In the PTZ kindling model, 
paralleling the strain-dependent nature 
of the adult lethality, female N7 
129S1/SvImJ Gnao1
+/G184S mice 
generally showed no difference in 
sensitization to PTZ kindling compared 
to wild-type littermates (Figure 3.3a), 
while as reported in Chapter 2 female 
B6 Gnao1+/G184S mutants were more 
sensitive to PTZ kindling than control 
(Figure 3.3b Gehan-Breslow-Wilcoxon 




Chr 17 locus modifies PTZ susceptibility 
We next tested the hypothesis that the Chr 17 spontaneous death modifier 
protected against the enhanced PTZ susceptibility. In this case, all experiments were 
restricted to females for reasons discussed in methods. Female F1 Gnao1 
+/G184S
 mice 
were protected from PTZ kindling sensitization compared to B6 Gnao1 
+/G184S
 female 
mice (Figure 3.4a, Gehan-Breslow-Wilcoxon df(1)=7.9 p < 0.01). This indicates, as in the 
spontaneous lethality, that a single copy of 129S alleles was sufficient for protection. 
129S alleles within just the Chr 17 41-70Mb modifier region also protected B6 female 
Gnao1 
+/G184S
 from sensitization to kindling (Figure 3.4b Gehan-Breslow-Wilcoxon 
df(1)=4.28 p<0.05).We then asked whether the Chr 17-mediated protection against 
kindling depended on the presence of the Gnao1 G184S allele. If so, that could indicate a 
specific interaction with Go and a gene product from the modifier region. If not, the 
region is likely to be a general modifier of kindling unrelated to our G protein mutant 
model. To address this, we compared female B6 Gnao1 
+/+
 mice both with and without 
the Chr 17 modifier for the rate at which they were sensitized. The region did not afford 
robust protection against PTZ sensitization (Figure 3.4c). While there may be a modest 
effect without the Gnao1 G184S allele, the striking effect in its presence prompted us to 
name this Chr17 locus Mogs1 (modifier of G protein-induced PTZ susceptibility 1) in 
parallel with the Moe1 and Moe2 loci which have been previously described for 
protection against spontaneous seizures induced by sodium channel mutants (Bergren et 
al. 2005; Bergren et al. 2009). 
The modifier Mogs1, however, does not appear to be the sole modifier locus. 
Analysis of F2 offspring from intercrosses of B6129SF1-Gnao1 
+/G184S
 mice showed that 
 
64 
only 4 out of 60 mice died before one year of age. Given that 25% of the F2 genome 
should be homozygous for B6 alleles at any given locus, 15 mice should have died if 
there was a single high-penetrance modifier region. Thus Mogs1 is likely to be one of two 





Figure 3.4 The locus on chromosome 17 also protects  
B6-Gnao1 +/G184S mice from sensitization to kindling. 
a) Female B6-Gnao1 
+/G184S
 female mice sensitize 
to kindling faster than female F1-Gnao1 
+/G184S 
mice demonstrating that a single copy of 129 
alleles is sufficient to delay sensitization to PTZ 
kindling (Gehan-Breslow-Wilcoxon df(1)=7.9 p < 
0.01). b) The onset of sensitivity to kindling for 
B6-Gnao1 
+/G184S 
mutants is delayed by the 
presence of a single copy of 129S alleles in the 41-
70Mb Chr 17 modifier region. c) In a sample of 
similar size to that in b, the Chr 17 modifier region 
did not significantly alter sensitization to PTZ 






One modifier is likely linked to 47Mb on Chr17 
 Given the size of the modifier region and large number of genes present therein I 
have developed several Gnao1 
+/RGSi
 lines that contain subregions of the 41-70Mb 
modifier. Regions currently developed include markers at 47Mb, 62Mb, 51-62Mb, and 
51-57Mb. Each of these lines contains 129 alleles at the locations listed in their name but 
are pure B6 at all the other test sites on Chr17. They are, however, not defined by whole 
genome mapping. Some still have 129 alleles on Chr5 or Chr16. Subsequent breeding 
will be required to produce true congenic mice containing the various Chr17 129 allele 
sets. Preliminary results using offspring of the 62Mb line, which has a single copy of 129 
alleles surrounding 62Mb on Chr17, rule out this region as a strong modifier. The Chr17 
47Mb line demonstrated significant protection for those mice retaining 129 alleles at 
47Mb alone (Figure 3.5b, Gehan-Breslow-Wilcoxon df(1)=.3.68 p < 0.05). Thus at least 
one modifier gene from Mogs1 is likely to occur between 41-51Mb as these mice are 
pure B6 outside of the 41 and 51Mb region on Chr 17. 
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Figure 3.5 One modifier within Mogs1 occurs between 41-51Mb 
Female Gnao1 
+/G184S
 mice were generated from a male carrying both a subregion of the 41-70Mb and the 
Gnao1G184S allele. a) 129S alleles around 62Mb on Chr17 appear unable to protect from kindling b) 129S 




In this Chapter I demonstrated that the PTZ kindling and spontaneous death were 
strain-dependent. This provided an experimental handle allowing us to identify a genetic 
modifier locus. The modifier region Mogs1 (Chr 17, 41-70 Mb) alters both the 
spontaneous death and PTZ-induced kindling phenotype in the Gnao1
 +/G184S mice. This 
region has been further refined by demonstrating that 41-51Mb is sufficient to afford 
protection (Mogs1a). However, the rest of the region has not been conclusively 
eliminated yet. Interestingly, the protective modifier alleles on Chr17 come from the 
129S strain, which is more sensitive to PTZ kindling compared to C57BL/6J. The 
modifier region also appears to have its effect on PTZ susceptibility in Go mutant mice 
but not control mice. Mogs1 also may not influence response to acute PTZ administration 
as it was not found in a genomic analysis of acute PTZ-induced seizures (high dose - 80 
mg/kg) in B6 vs DBA mice (Ferraro et al. 1999). These two observations suggest that 
this modifier region (Mogs1) may have a unique interaction with Go function in PTZ 
kindling-type remodeling mechanisms.  
The Mogs1 region (41-70Mb) includes the coding sequences of ~ 130 known 
proteins. One that was an obvious candidate was Rab5a protein which has been proposed 
as a novel Go effector in studies in Drosophila (Purvanov et al. 2010). Loss of an effector 
molecule could easily suppress a gain-of-function mutation in Go. There are no non-
synonymous coding SNPs in Rab5a and despite several SNPs in the 5' and 3' UTR, there 
were no changes in mRNA expression as detected by quantitative real-time PCR (data 
not shown). Thus it is unlikely that Rab5a is the modifier gene. To develop a list of other 
possible candidates, we looked for non-synonymous SNPs or splice site variants 
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identified in the Sanger informatics website (Table 3.1). Three proteins have altered stop 
codons. Two genes, 9130008F23Rik K55* and Trem2 149*, have premature stops while 
Yipf3 lost a stop codon, *202W. The gene Polh has a variant in a splice site while Ttbk1, 
Tbc1d5 and Lrfn2 have in-frame dels in the 129S sequence. For non-synonymous SNPs, 
the predicted effect on protein function was assessed using Provean (Choi et al. 2012). 
Seven genes Pgk2, Gpr115, Gm5093, BC048355, Lrfn2, Kcnh8 and Vmn2r118 were 
predicted to have non-synonymous SNPs disruptive of protein function in the 129S 
strain. Given that the informatics databases that I had access to may be incomplete and 
that distal SNPs may influence gene expression, a high-priority candidate list of 20 genes 
with known CNS function or a role in GPCR signaling was generated regardless of 
Sanger SNP status (Table 3.2). These lists represent a starting point for future candidate 
analysis in conjunction with higher resolution experimental mapping of Mogs1. Whole 
exome and targeted exome sequencing is currently underway. 
 The approach that we took to find this modifier region started from N7 mice in 
which significant selection for loci affecting survival of the mutants may have already 
occurred. Consequently, it cannot be concluded that Mogs1 is the only modifier. Indeed, 
a more unbiased approach suggests that it is not. Analysis of F2 crosses from (C57BL/6J 
x 129/SvImJ Gnao1 +/G184S)F1 mice showed that only 4 out of 60 mice died before one 
year of age. Given that 25% of the F2 genome should be pure B6, 15 mice should have 
died if there was a single high-penetrance suppressor region. Thus Mogs1 is likely one of 
two or more modifier regions. 
The present results buttress recent work implicating alleles encoding GPCRs, 
RGS proteins, and Go as candidates in future human genetic analyses of epilepsy. Only 
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12 non-synonymous SNPs were reported in GNAO1 in the exome variant server database 
out of ~13,000 alleles tested (evs.gs.washington.edu). Most were conservative, 
suggesting that damaging mutations may not be tolerated for medallion inheritance. 
However paralleling the de novo mutations found in severe early onset epilepsies, a 
recent report by Nakamura et al. documented de novo mutations in GNAO1 in four 
patients with epileptic encephalopathy (Nakamura et al. 2013). Interestingly one of the de 
novo mutations also occurs within the switch II region of Go, as our G184S mutation 
does, and involves a similar substitution of a bulky amino acid for glycine. Thus, while 
not likely to contribute to inherited epilepsies, GNAO1 may be a particularly important 
candidate to consider when structural abnormalities of the brain are comorbid with 
epilepsy in human patients. Studies of our animal model should also provide an attractive 
opportunity to learn more about brain function and treatment options in these patients. 
 In this chapter we defined a novel epilepsy modifier locus, Mogs1, on Chr 17. The 
mechanism underlying this model, enhanced Go signaling, is a surprising cause of a 
seizure disorder as Gi/o signaling has typically been thought to have neuroinhibitory 
actions. This could, however, result from an overall greater inhibition of inhibitory 
signaling leading to a net gain in excitatory signaling. Our results thus suggest new 
candidate genes for genetic epilepsies. Also the modifier effect is consistent with an 
emerging recognition that complex diseases may depend on multiple rare mutations, 
preventing their detection in large GWA studies (Sisodiya & Mefford 2011; Tan et al. 
2004). A better understanding of Go signaling in seizure disorders may facilitate the 
identification of novel GPCR drug targets for epilepsy. 
 
70 
Materials and Methods 
Animal studies were performed in accordance with the Guide for the Care and 
Use of Laboratory Animals established by the National Institutes of Health; all 
experimental protocols were approved by the University of Michigan Committee on the 
Use and Care of Animals. Experiments were performed using male and female mice as 
indicated in methods below. All experimental mice were group-housed with unlimited 
access to food and water until experimentation. Lights were maintained on a 12 hour 
light/dark cycle with lights on at 5:00/6am depending on time of year. All experiments 
were conducted during the light phase with the exception of the EEG video recordings 
which were throughout the light cycle. 
Generation of Gnao1 
+/G184S
 mice and perinatal viability experiments 
Most details were reported in Chapter 2. Only additional details are provided here. 
A single N6 B6-Gnao1
+/G184S
 male ancestor gave rise to all B6-Gnao1
+/G184S
 mice 
presented in this study. The reduced viability and premature lethality of the Gnao1
+/G184S
 
mutants reported in chapter 2 precluded congenic development due to strain collapse by 
N10. Thus, data presented in this paper are from N7, N8, and N9 which will collectively 
be referred to as B6. To control for the genetic variability within the generations, we 
tested regions that had 129S alleles present in the N6 founder to ensure that retention of 
other 129S regions did not influence the results. All B6129SF1-Gnao1
+/G184S
 and 
littermate control mice were generated from crosses with Gnao1
+/G184S
 129S1/SvImJ 
male mice and C57BL/6J females to ensure genetic homogeneity. 
Genotyping 
See Chapter 2 for details on genotyping. For genome-wide SNP analysis mouse 
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tail DNA was purified using proteinase K (Invitrogen) digestion followed by ethanol 
precipitation. 
Viability 
Data on survival to weaning was determined by observed genotype frequencies of 
male and female mice at 2-3 weeks of age using 41 N4 129S1/SvImJ (25 males and 16 
females) and 55 N4 B6;129 (29 males and 26 females) offspring from heterozygote x 
heterozygote crosses. For adult survival in Figure 3.1 data were collected from 36 N6 
129S1/SvImJ-Gnao1
+/G184S
 (10 males 26 females) and 18 N7 B6.129 -Gnao1
+/G814S
 (11 
males and 7 females) group-housed mice. All N7 B6 mice in this figure were sired by the 
single N6 B6 founder male crossed to C57BL/6J females that were within F4 generations 
from mice purchased directly from Jackson Labs.  
Identification of modifier region 
To determine whether the protective effect of the 129S1/SvImJ background on 
spontaneous lethality was dominant, we generated mutant B6129SF1 mice from an N7 
129S1/SvImJ male mouse carrying the Gnao1 G184S allele and assessed them for deaths 
out to 47 weeks of age (see results). After determining that 129S alleles were dominant in 
protecting from premature lethality we employed a genome-wide scan on the 18 mice 
from the survival curve study in Figure 3.1b (11 N7F0 B6 -Gnao1
+/tm2Rneu
 males & 7 
females) to identify regions where 129S alleles were preferentially retained in mice that 
lived past the early phase of mortality (i.e. 25 weeks). The scan was performed utilizing 
an Illumina GoldenGate medium density mouse panel at the University of Michigan 
Sequencing core. A confirmation study on Chr 17 was then done to overcome the low 
power of the initial screen and reduce the modifier’s size using an independent cohort of 
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drug naïve, group-housed B6-Gnao1
+/G184S
 mice (10 males & 4 females retain 129 on 
Chr17, 12 females & 18 males lack 129 on Chr17). They carried 129S alleles at 47Mb 
and 62Mb on Chr17 but had only B6 alleles by 41Mb and 70Mb. Tests were also 
performed on Chr 5 and Chr16 as covariates to ensure they did not influence the results 
as these mice were not congenic for 129S only on Chr 17. 
Each primer pair amplified two discrete SNPs identified on the Jackson lab 
informatics website (informatics.jax.org) to limit sequencing errors. DNA sequences 
surrounding the two SNPs were obtained from the UCSC Genome Browser 
(http://genome.ucsc.edu/cgi-bin/hgGateway NCBI37/mm9 NCBI37/mm9 build). Primers 
were then designed using Primer 3 (http://frodo.wi.mit.edu/primer3/ v.0.4.0) using the 
rodent mispriming database and only primers that were a minimum of 60 bases and a 
maximum of 600 bases from the desired SNPs were selected. PCR primers and the SNPs 
tested are listed in Table 3.3. All PCR reactions were performed with the same cycling 
parameters and reagent concentrations used for genotyping except the annealing 
temperature was 59
o
C. PCR products were isolated by ethanol precipitation and 
sequenced by the University of Michigan DNA Sequencing Core. Chromatograms were 
analyzed to determine which alleles were carried within the modifier region. 
Seizure susceptibility and epileptogenesis susceptibility 
See Chapter 2 methods for details on the kindling protocol. For comparison across 
strains, we relied on the fact that kindling is a repeated process and thus should sample 
various points within the estrus cycle as different strains of mice must be housed 
separately. To assess the ability of the Chr17 modifier to influence response to PTZ, we 
only analyzed mutant B6 females. Females were group housed together a minimum of 
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two weeks prior to initiation of kindling. Experiments were limited to females due to the 
limited number of mutant males available for breeding, and animal use protocol 
requirements that preclude combining males from separate litters which would have 
increased environmental variability. 
Candidate gene identification 
The exhaustive list of candidate genes was generated with Biomart 
(http://www.ensembl.org/biomart/martview). A list of known non-synonymous SNPs 
within the modifier region was generated from the Sanger informatics website 
(http://www.sanger.ac.uk/resources/mouse/genomes/). These were then translated into 
relative amino acid substitutions for specific splice variants using Ensembl. Provean, a 
computational method with predictive power similar to SIFT and PolyPhen-2 was then 
used to determine likely functional consequences (http://provean.jcvi.org/index.php) 
(Choi et al. 2012). 
Statistical analysis 
 
Data were analyzed using GraphPad Prism 5.0 and GraphPad QuickCalcs 
(GraphPad; LaJolla, CA). Chi squared analysis was used to evaluate deviation from 
Mendelian ratios. Proportionality of hazards for survival curves were analyzed using SAS 
9.3 (SAS Institute; Cary, NC). The Gehan-Breslow-Wilcoxon test was applied to survival 
and kindling data as opposed to logrank because the survival curves failed to meet the 
proportional hazard assumption required for valid application of logrank (Machin et al. 
2006). In analysis of EEG data, a parametric unpaired t-test was performed assuming 
populations with different standard deviations using Welch’s correction. Two-tailed P 




Ensembl Gene ID Gene Number of SNPs Predicted Effect 
of coding nsSNPs 
  5’UTR NSC 3’UTR  
ENSMUSG00000031233 Pgk2 
 1  Deleterious 
ENSMUSG00000090747 Gm17495 1 3*  Neutral 
ENSMUSG00000073396 Gm6084  1 1 Neutral 
ENSMUSG00000023930 
Crisp2 1  1  
ENSMUSG00000023926 Rhag 1  1  
ENSMUSG00000054951 9130008F23Rik  6  Premature stop 
ENSMUSG00000091043 Glyatl3  2*  Neutral 
ENSMUSG00000023919 Cenpq 4 3  Neutral 
ENSMUSG00000023921 
Mut   15  
ENSMUSG00000042256 
3110082D06Rik   29  
ENSMUSG00000023918 Gpr115 3 4 10 Deleterious 
ENSMUSG00000057899 Gpr111  3 3 Neutral 
ENSMUSG00000061665 CD2ap 1 2 5 Neutral 
ENSMUSG00000023915 Tnfrsf21 3 1 6 Neutral 
ENSMUSG00000041293 Gpr110 2 3 5 Neutral 
ENSMUSG00000056492 Gpr116   44  
ENSMUSG00000023914 Mep1a   1  
ENSMUSG00000023913 Pla2g7 1 1 3 Neutral 
ENSMUSG00000040140 Tdrd6  8  Neutral 
ENSMUSG00000023912 Slc25a27   1  
ENSMUSG00000023963 Cyp39a1  2 3 Neutral 
ENSMUSG00000039601 Rcan2 1    
ENSMUSG00000023960 Enpp5 2 2 1 Neutral 
ENSMUSG00000023961 
Enpp4 
  20  
ENSMUSG00000023959 Clic5   22  
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ENSMUSG00000039153 Runx2 4  9  
ENSMUSG00000038954 Supt3h 1    
ENSMUSG00000023932 Cdc5l 
 2# 1 All NSC low 
confidence 
ENSMUSG00000023949 Tcte1   1  
ENSMUSG00000096847 Tmem151b 
 1#  All NSC low 
confidence 
ENSMUSG00000037089 Slc35b2 1  1  
ENSMUSG00000023951 Vegfa   1  
ENSMUSG00000034509 MaD2L1bp  1  Neutral 
ENSMUSG00000023952 Gtpbp2 1  3  
ENSMUSG00000023953 Polh 2 2*  Neutral 
ENSMUSG00000067150 Xpo5  2  Neutral 
ENSMUSG00000071074 Yipf3  1 3 Premature stop 
ENSMUSG00000071073 
Gm88  1*   
ENSMUSG00000012296 Tjap1 2 1 1 Neutral 
ENSMUSG00000032842 Abcc10 3    
ENSMUSG00000015597 Zfp318 2 2 1 Neutral 
ENSMUSG00000067144 Slc22a7  2  Neutral 
ENSMUSG00000091742 Gm5093  6*  Deleterious 
ENSMUSG00000015599 Ttbk1  3# 8 Neutral 
ENSMUSG00000040658 BC048355  3 1 Deleterious 
ENSMUSG00000040327 Cul9 1 6*  Neutral 
ENSMUSG00000015605 
Srf 
1  3  
ENSMUSG00000023972 Ptk7  2 2 Neutral 
ENSMUSG00000003546 
Klc4 
  3  
ENSMUSG00000038545 Cul7 1 1  Neutral 
ENSMUSG00000063576 Klhdc3  1  Neutral 
ENSMUSG00000002768 
Mea1 
  2  
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ENSMUSG00000059409 Ppp2r5d 2  4  
ENSMUSG00000002763 Pex6 1 1 1 Neutral 
ENSMUSG00000023973 Cnpy3  1 5 Neutral 
ENSMUSG00000062619 2310039H08Rik 1    
ENSMUSG00000063888 Rpl7l1   3  
ENSMUSG00000036568 BC032203   1  
ENSMUSG00000036430 
Tbcc 
  1  
ENSMUSG00000023978 Prph2   2  
ENSMUSG00000023977 Ubr2   1  
ENSMUSG00000064043 Trerf1  2*  Neutral 
ENSMUSG00000034729 Mrps10 6 3  Neutral 
ENSMUSG00000023979 Guca1b  2 13 Neutral 
ENSMUSG00000023982 Guca1a 3 1  Neutral 
ENSMUSG00000047150 1700001C19Rik  1 5 Neutral 
ENSMUSG00000034382 AI661453  1* 1  
ENSMUSG00000034165 
Ccnd3 
1    
ENSMUSG00000090115 Usp49   1  
ENSMUSG00000032717 Mdfi  2 2 Neutral 
ENSMUSG00000073386 9830107B12Rik   4  
ENSMUSG00000042265 Trem1   6  
ENSMUSG00000051682 Treml4  3 3 Neutral 
ENSMUSG00000071068 Treml2 2 2 4 Neutral 
ENSMUSG00000023992 Trem2  6 3 Premature Stop 
ENSMUSG00000023994 Nfya 2  5  
ENSMUSG00000040771 AI314976 2  1  
ENSMUSG00000040694 Apobec2  1 1 Neutral 
ENSMUSG00000023995 Tspo2   1  
ENSMUSG00000043592 Unc5cl  1 7 Neutral 
ENSMUSG00000040490 Lrfn2  1  Deleterious 
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ENSMUSG00000023999 Kif6   22  
ENSMUSG00000039316 Rftn1  1 2 Neutral 
ENSMUSG00000067103 AY702103   16  
ENSMUSG00000010592 
Dazl 
1  2  
ENSMUSG00000044645 Gm7334  1*   
ENSMUSG00000023923 Tbc1d5 1 1# 23  
ENSMUSG00000035580 Kcnh8  1  Deleterious 
ENSMUSG00000017831 
Rab5a 
1  4  
ENSMUSG00000044957 4921523A10Rik  1  Neutral 
ENSMUSG00000000708 Kat2b 1  1  
ENSMUSG00000023940 Sgol1 4 5 4 Neutral 
ENSMUSG00000023122 Sult1c2 2    
ENSMUSG00000023945 Slc5a7 1  16  
 Gm17474  4^   
ENSMUSG00000024172 St6gal2 1 1 36 Neutral 
ENSMUSG00000091504 Vmn2r118  7  Deleterious 
ENSMUSG00000024174 Pot1b  1 9 Neutral 
ENSMUSG00000032915 
Emr4 
  1  
ENSMUSG00000002831 Plin4 1 1 1 Neutral 
ENSMUSG00000001228 Uhrf1   1  
ENSMUSG00000013236 Ptprs   1  
ENSMUSG00000042625 Safb2  3* 6 Neutral 
ENSMUSG00000071054 Safb   2  
ENSMUSG00000049760 2410015M20Rik   1  
ENSMUSG00000041168 Lonp1  1  Neutral 
ENSMUSG00000054723 Vmac   1  
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ENSMUSG00000002379 Ndufa11 1    
ENSMUSG00000024207 Acsbg2 1 1 1 Neutral 
ENSMUSG00000024209 1700061G19Rik   1  
ENSMUSG00000024212 Mllt1   2  
ENSMUSG00000045019 Acer1   5  
ENSMUSG00000002660 Clpp   1  
ENSMUSG00000002664 Pspn  1  Neutral 
ENSMUSG00000007670 Khsrp 1 1* 4  
ENSMUSG00000046329 Slc25a23   1  
ENSMUSG00000044279 Crb3 1 1 2 Neutral 
ENSMUSG00000002668 Dennd1c  1  Neutral 
ENSMUSG00000038048 Cntnap5c  2  Neutral 
ENSMUSG00000024227 2610034M16Rik   6  
ENSMUSG00000023965 Fbxl17   2  
Table 3.1 Variants between C57BL/6J and 129S1/SvImJ between 41-70Mb on Chromosome 17 
Non-synonymous SNPs (nsSNPs) in the coding region and SNPs in 5' or 3' UTRs were determined between 
the C57BL/6J and 129S1/SvImJ strain using the Sanger Mouse Genomes Project website. Effects of non-
synonymous SNPs were predicted using Provean with a cutoff score of -2.5. See methods for details. * 
Indicates not all SNPs could be identified in Ensembl and thus the prediction is only based on those SNPs 
that were found in both Sanger and Ensembl. # Indicates some or all of the predicted SNPs are low 
confidence and were not used to compute potential changes in protein function. ^ Indicates that the protein 





Gene Location on 
Chr 17 (Mb) 
Function Reference 
Gpr115 42.79 Orphan GPCR  
Gpr111 42.84 Orphan GPCR  
Gpr110 43.4 Orphan GPCR  
Gpr116 43.5 Orphan GPCR  
Rcan2 43.94 Regulates calcineurin activity in brain (Porta et al. 
2007) 
Slc29a1 45.72 Transporter that regulates adenosine levels and controls sensitivity 
to ethanol withdrawal induced seizures 
(Kim et al. 
2011) 
Gtpbp2 46.29 GTPase of unknown function  
Ubr2 47.1 Influences neural stem cell development (Naujokat 
2009) 
Foxp4 48 transcription factor involved in brain development (Takahashi 
et al. 2008) 
Mocs1 49.6 Deficiency leads to altered EEGs (Sie et al. 
2010) 
Satb1 51.9 Controls dendritic spine density during development (Balamotis 
et al. 2012) 
KcnH8 52.7 Potassium channel in a region linked to temporal lobe epilepsy (Combi et 
al. 2005) 
Rab5a 53.6 Putative Go effector (Purvanov 
et al. 2010) 
Slc5a7 54.4 choline transporter (Sales et al. 
2010) 
St6gal2 55.6 Sialylation affects neural plasticity (Okabe et 
al. 2001) 
Sema6b 56.3 maturation of dendritic spines (Pasterkamp 
& Giger 
2009) 
Nrtn 56.9 KO has reduced hippocampal kindling (Nanobashv
ili et al. 
2000) 
Pspn 57.1 neuronal survival and outgrowth (Yang et al. 
2004) 
Gpr108 57.4 Orphan GPCR  
Table 3.2 Candidate Genes in the extended Chr17 region (41-70Mb) based upon function 
The gene list for the entire conservative estimate of the modifier region from 39-65.5Mb on Chr 17 was 
examined using Biomart. A literature search was performed for each gene for a connection to epilepsy, 
GPCR signaling, seizure threshold and sudden death. Those genes with a connection to one of the search 






Forward Primer Reverse Primer 
rs29685319 
rs29546941 
5 – 5.9Mb Tcaggaaaccctactccccta tcattgcaagaaagccaaact 
rs4221298 
rs4221299 
16 - 96Mb Tccaaggaggccaaagatact aaaaacagggtacaggcatcc 
rs33479194 
rs13482982 
17 – 41Mb Ctgtgttcccaaccacctct tctagtcagtgcctcgctca 
rs29605468 
rs33703249 
17 - 47Mb Tggcaagacgtgttcattttc tcagagggcttttgaggagag 
rs33050836 
rs29523235 
17 - 62Mb Ggtcatctggaggagcaacc gaacgcgagtgacttgatgc 
rs33464243 
rs33400606 
17 – 70Mb Catggcctcaggtaggtgata tttgaactgcttgaaggaagc 
Table 3.3 Primer sequences for each SNP tested 
Regions of retained 129S alleles on each chromosome were analyzed using the Jackson Lab informatics 
website to identify a test site with two SNPs within a 100 bp region. DNA sequences flanking this region 
were then obtained from the UCSC Genome Browser and subjected to primer design using the primer3 




Chapter 4  
Disruption of GIRK channel activation in Go gain-of-function 
mice 
Summary 
Chapter 2 provided an initial characterization of the Gnao1 
+/RGSi
 mice. The 
chapter also highlighted a conundrum in that mutant mice are susceptible to PTZ kindling 
despite initial expectations they would be protected. Chapter 3 worked towards dissecting 
the mechanism behind the enhanced spontaneous death and susceptibility to PTZ 
kindling using a genetic approach. Now I will shift gears to approach the problem from a 
receptor-centric view by working to better understand signaling through three receptor 
systems implicated in epilepsy, GABAB,, μ-opioid, and 5-HT1A.  
Here I demonstrate that Gnao1 
+/RGSi
 exhibit normal motor impairment due to 
baclofen, but exhibit substantially less hypothermia. Gnao1 
+/RGSi
 mice also experience 
diminished hypothermia due to a variety of pharmacological treatments known to depend 
upon GIRK channel function. The altered response of Gnao1 
+/ RGSi
 mice may be due to 
diminished GIRK signaling within the Periaqueductal Gray (PAG), a key region in 
thermoregulation. The decrease in GIRK channel activity is unlikely to be due to a simple 




 This work was highly collaborative. I designed all experiments and then 
instructed and supervised undergraduates who performed the work with the following 
exceptions: 1) Nick Senese generated the morphine hypothermia data following my 
protocols 2) Susan Ingram and Minghua Li designed and planned all electrophysiology 
involving the PAG. Past and current undergraduates who meaningfully contributed to this 
work by running behavioral experiments include Kevin Kohut, Matthew Stern, and Hans 
Dalton. 
Introduction 
 Side-effects of clinically prescribed drugs are a major health problem. Roughly 
30% of patients on medication for a chronic condition stop treatment due to side-effects 
(Dusing et al. 1998; Hugtenburg et al. 2006). This and other issues of non-compliance 
with prescription drugs are associated with $289 billion in annual healthcare costs and 
lead to over 100,000 deaths per year within the US alone (Viswanathan et al. 2012). With 
many current therapies focused on activation of G-protein Coupled Receptors (GPCR), it 
may be impossible to pharmacologically separate on-target effects from side-effects. For 
example baclofen, a GPCR agonist, induces both muscle relaxation and disrupts 
thermoregulation through GABAB receptor activation (Costa et al. 2005; Pravetoni & 
Wickman 2008). 
Through modulation of G-protein activity downstream of GPCR activation it may 
be possible to potentiate desired effects while minimizing side-effects. This is a result of 
the region specific localization of G-proteins and their negative regulators, the Regulators 
of G-protein Signaling (Blazer & Neubig 2009). For example, we recently demonstrated 
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that mice with enhanced Gi2 signaling have enhanced 5-HT1A mediated antidepressant 
action without altering 5-HT1A mediated hypothermia (Talbot et al. 2010). 
 In this work I specifically chose to focus on one clinically relevant side-effect, 
disruption of thermoregulation. Two to three percent of patients treated with anti-
psychotics will develop hyperthermia associated with Neuroleptic Malignant Syndrome 
(NMS) (Mann & Lazarus 2003). NMS has also been observed in the treatment of 
Parkinson's disease and with the use of the anti-spastic agent baclofen (Mann & Lazarus 
2003; Turner & Gainsborough 2001). A host of other drugs, including anti-depressants 
(SSRIs, MOIs) and ecstasy (MDMA), can induce CNS-mediated hyperthermia (Eyer & 
Zilker 2007). As of 2004, ecstasy-induced hyperthermia was treated by ice baths 
(Fantegrossi et al. 2004). With treatment, the aforementioned hyperthermia syndromes 
are still lethal in 40% of patients (Mann & Lazarus 2003). With several distinct drug 
classes potentially leading to fatal hyperthermia further research in how these drugs alter 
thermoregulation is warranted. 
The inhibitory G-protein family, Gi/o is known to mediate actions of a variety of 
GPCRs that disrupt thermoregulation through G-protein-coupled Inwardly-Rectifying 
Potassium (GIRK) channel activation, including – 5-HT1A, GABAB, and the µ opioid 
receptors (Albert & Robillard 2002; Costa et al. 2005). Unfortunately, in vitro transfected 
systems are typically unable to identify which Gi/o family member is responsible for a 
given signaling output (Fernandez-Fernandez et al. 2001). This is compounded by the 
difficulty of extrapolating from a cellular response to a physiological one.  
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I hypothesize that distinct Gi/o family members are involved in specific subsets of 
the therapeutic and/or side-effects of many clinically relevant drugs.  
 Here I demonstrate that mice with enhanced Go signaling experience expected 
motor impairment due to baclofen, but exhibit substantially less hypothermia. Gnao1 
+/RGSi
 mice also experience diminished hypothermia due to a variety of pharmacological 
treatments known to depend upon GIRK channel function. The altered response of 
Gnao1 
+/ RGSi
 mice may be due to diminished GIRK signaling within the Periaqueductal 
Gray (PAG), a key region in thermoregulation (Romanovsky 2007); (Bachtell et al. 2003; 
Yoshida et al. 2005); (de Menezes et al. 2006). The decrease in GIRK channel activity is 
unlikely to be due to a simple loss-of-function of the mutant Gα subunit as mice lacking 
50% of Go do not have equivalent changes. Thus we have demonstrated, for the first time, 





 mice have decreased hypothermia but equivalent or slightly enhanced 
motor impairment due to baclofen 
 Given that GABAB receptors are thought to signal through Go (Campbell et al. 
1993; Greif et al. 2000), we tested two physiological outputs of GABAB receptor 
activation, hypothermia and motor impairment. Each of these effects is thought to be due 
to GIRK channel activation (Costa et al. 2005; Pravetoni & Wickman 2008). However, 
different brain regions are likely involved. The neural basis of baclofen-mediated ataxia 
has been localized to the cerebellum, a region not associated with thermoregulation 
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(Maity et al. 2012). B6-Gnao1 
+/RGSi
 male mice have reduced hypothermia but normal 
motor impairment in response to baclofen administration (Figure Figure 4.1, Two-way 





Figure 4.1 Gnao1+/RGSi mice have an altered response profile to baclofen 
A) Hypothermia is reduced in response to escalating doses of baclofen 
in B6-Gnao1 
+/RGSi
 mice. B) Hypothermia is reduced in response to a 
6mg/kg baclofen in B6-Gnao1 
+/RGSi
 mice. C) Motor impairment is 
equivalent across genotypes due to escalating doses of baclofen. D) 
Kinetics of motor impairment are unaffected by genotype. 
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 mice have decreased pharmacologically induced hypothermia by other 
drugs that act through GIRK channels 
Due to limited viability of mutant mice on the B6 background we switched to 
using B6129F1 mice (F1). In Figure 4.2A we reproduce the defect in baclofen-mediated 
hypothermia in F1 Gnao1 
+/RGSi
 mice indicating that the phenotype is not background-
dependent (2-way ANOVA, F(1, 7) = 8.26 p=0.02). F1 Gnao1 
+/RGSi
 mice also have a 
reduction in hypothermia due to 5-HT1A and μ-opioid receptors as assessed by their 
respective agonists, 8-OH-DPAT and morphine. Each receptor is known to induce 
hypothermia, in part, through GIRK channels (Figure 4.2B morphine single-dose F(1,8)= 
88.97 p<0.0001; Figure 4.2C single-dose 8-OH-DPAT 2-way ANOVA F(1,14)=43.41 p< 






Figure 4.2 GIRK mediated hypothermia is disrupted in F1 Gnao1 +/RGSi mice 
A) Hypothermia due to baclofen is attenuated in F1 Gnao1 
+/RGSi
 mice as 
assayed by an escalating dose response curve. B) Both the maximal response 
and time course of 30 mg/kg morphine mediated hypothermia is altered in F1 
Gnao1 
+/RGSi
 mice as assayed by a single dose time course. C) Both the 
maximal response and time course of 1mg/kg 8-OH-DPAT mediated 
hypothermia is altered in F1 Gnao1 
+/RGSi
 mice as assayed by a single dose 
time course. D) 8-OH-DPAT mediated hypothermia is reduced in F1 Gnao1 
+/RGSi
 mice as assayed by an escalating dose response curve. 
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 mice have a normal hypothermia response to drugs that act 
independent of GIRK channel activity 
The reduced hypothermia in Figure 4.2 could be due to a global disruption of 
thermoregulation. Therefore we tested D2-like receptor-mediated hypothermia which is 
known to be independent of GIRK channel function (Costa et al. 2005). It has been 
postulated to be mediated through a presynaptic mechanism (Zarrindast & Tabatabai 
1992). In Figure 4.3, it can be seen that the Go mutation has no statistically significant 
influence on the hypothermia response in an equivalently powered experiment. Thus the 
defect in hypothermia is pathway-dependent and not a universal downstream defect. 
  
Figure 4.3 Non-GIRK channel mediated hypothermia is 
preserved in F1 Gnao1 +/RGSi mice 
Non-GIRK channel dependent hypothermia was 
tested using 0.5 mg/kg of the D2-like agonist 






 mice have decreased GABAB and μ-opioid receptor (MOR) activation 
of GIRK channel activity in the PAG 
While the in vivo changes in hypothermia are indicative of decreased GIRK 
channel activation, this could also have been due to effects up-or downstream of the 
GIRK channel in the hypothermia pathway. Therefore to reduce the level of system 
complexity, I collaborated with the Ingram laboratory to directly test GIRK activity 
within the periaqueductal gray area (PAG), a region known to play a central role in 
thermoregulation and to contain both GABAB and MOR receptors (Romanovsky 2007). 
Here we found a decrease in the magnitude of both GABAB and the MOR receptor-
mediated stimulation of GIRK channel currents (Figure 4.4). These data indicate that 





Figure 4.4 GPCR activation of GIRK channel currents is reduced in Gnao1 +/RGSi mice 
A) Baclofen (10 µM) activates GIRK channel currents in PAG neurons in control mice but had a 
minimal response in neurons of the Gnao1 
+/RGSi
 mice (t-test, t(6) = 2.906, p < 0.05). B) The μ-opioid 
receptor agonist met-enkephalin (ME) activates GIRK channel currents in control mice but the 
magnitude of the current is substantially reduced in Gnao1 
+/RGSi
 mice (F(1,11) = 6.354, p < 0.05).  
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Reduced Go function does not explain altered hypothermia 
 Given that the mutation was designed as a gain-of-function mutation, it was 
unexpected to see the loss of signaling. One potential way this mutation may result in a 
loss of function is through a reduction in protein level. It has been previously reported 
that 129S1/SvImJ Gnao1 
+/ RGSi
 mice exhibit a slight reduction in Go protein level 
(Lamberts et al. 2013). This was not found in our own hands on the F1 background 
(Figure 2.2). To further assess whether reduced Go protein could cause this effect, we 
tested Gnao1 
+/-
 mice which have a 50% reduction in protein levels (Lamberts et al. 
2011). They still, however, exhibited normal 8-OH-DPAT induced hypothermia (Figure 
4.5). 
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Figure 4.5 A 50% reduction in Go protein does 
not impair GIRK-dependent hypothermia 
1mg/kg of 8-OH-DPAT was administered to 




Transcriptional regulation does not explain decreased GIRK channel activation 
Compensatory mechanisms may reduce transcription of key components within 
the signaling cascade. Therefore we checked GIRK and several other CNS proteins in 
both the hippocampus and cortex of F1 Gnao1 
+/RGSi
 males. Unfortunately, while an area 
of interest, the PAG could not be isolated due to technical limitations. Figure 4.6 
illustrates that despite seeing the expected increase of RGS4 within the cortex, no 
difference in GIRK was detected due to the mutation in either brain region. 
Discussion 
Here we support the 
hypothesis that modulating G-
protein signaling is able to 
selectively influence a subset of 
responses to a given 
pharmaceutical. Specifically, in 
this Chapter, I demonstrate 
Gnao1 
+/RGSi
 mice to have reduced 
baclofen-mediated hypothermia 
while the baclofen-mediated motor impairment is comparable to control. Further, this 
chapter demonstrates that morphine-induced hypothermia is reduced in mutant mice, 
despite previous reports demonstrating that the mutation enhances morphine-induced 
supraspinal antinociception (Lamberts et al. 2013). The reduction in hypothermia appears 
to be due to a disruption of GIRK channel activation within the PAG. These findings do 
Figure 4.6 GIRK transcription in cortex and hippocampus is 
unaltered 
mRNA levels for several excitatory and inhibitory signaling 
components were quantified using GAPDH for normalization. 
Cortex and hippocampus of mutant and control mice were 
assayed. The mutation did not influence mRNA levels. 
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not appear to be due to a loss of Go function nor does it appear to due to disruption of 
transcriptional control of GIRK channels. 
Historically, many labs have had difficulty in differentially modulating baclofen’s 
hypothermia and motor-impairing effects. Gabbr1 
-/-
 mice, which lack GABAB receptors, 
lose both effects indicating that a single receptor is responsible for both actions of the 
drug (Schuler et al. 2001). It also appears that both effects, in addition to being through 
the same receptor, are also due to the same effector, GIRK2 containing channels. Kcnj6 
-/-
 
mice have a significant loss in both measures of baclofen action (Costa et al. 2005); 
(Pravetoni & Wickman 2008). However Maity et al. recently identified the pathways 
upon which baclofen acts to induce muscle relaxation within the cerebellum (Maity et al. 
2012). Within the signaling cascade they identified RGS6 as a key modulator and 
confirmed that Rgs6 
-/-
 mice were dramatically sensitized to the motor-impairing effects. 
Conspicuously missing, however, is the impact that RGS6 has on other baclofen-
mediated effects such as sedation or hypothermia.  
The selective disruption in baclofen-mediated hypothermia in Gnao1 
+/RGSi
 mice 
appears to be due to altered GIRK channel activity. Gnao1 
+/RGSi
 mice have significantly 
reduced hypothermia in response to several drugs which induce hypothermia in a GIRK 
channel-dependent manner (Figure 4.1 & Figure 4.2). However quinpirole-mediated 
hypothermia, which acts independently of GIRK channels, is intact. This likely implies 
that central downstream thermoregulatory pathways are still intact. 
One may argue that by providing a large dose of quinpirole we have masked an 
effect on a central downstream hypothermia pathway, however this is unlikely. The dose 
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of quinpirole administered generated a comparable magnitude drop in core temperature 
as compared to those drugs that were GIRK channel-dependent. Further, it was not a 
maximal response as a dose of 1 mg/kg generated a two degree larger drop  and the 
mutation had no effect on that response either (data not shown). 
Another interesting conclusion to be drawn from these data is that enhanced Go 
activity must not universally impact GIRK channel signaling. Girk2 
-/-
 mice and Girk1 
-/-
 
mice lack a baclofen-mediated motor impairment. Therefore if the disruption in GIRK 
channel activity was universal across the brain of Gnao1 
+/RGSi
 mice they should have a 
blunted motor impairment responses as well. Yet based upon Figure 4.1 this is not the 
case. 
It was quite challenging to understand how a gain-of-function mutation would 
lead to a reduction in physiological signaling. Therefore we looked at the 
electrophysiological level which further confirmed that, at least within the PAG, GIRK 
channel activity was significantly reduced. There are at least four possible explanations 
for this finding including: reduced expression of G-protein, reduced GIRK channel, 
reduced receptor levels, or a role for RGS action to enhance G-protein-mediated GIRK 
signaling. Unfortunately, in light of data presented here and in other works, none of these 
hypotheses appear reasonable. First, loss of Go function appears unlikely as we tested if a 
50% reduction in protein level could phenocopy the blunted hypothermia but found a 
normal hypothermic response to 8-OH-DPAT in heterozygote Gnao1 
+/-
 mice. Second, 
we explored the potential role for transcriptional control of Kcnj6 to be a mediator of our 
observations. This is based upon a prior report indicating that Go signaling can suppress 
transcription of N-type calcium channel activity (Kim et al. 2003). However, I found the 
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mutation to have no effect within the cortex and the hippocampus. As mentioned above 
though, a brain region selective impact may be responsible; therefore a more robust 
analysis of mRNA from other brain regions, including the PAG, will be needed to fully 
eliminate this mechanism. The third potential explanation for the blunted hypothermia is 
that loss of RGS/G protein interactions diminishes GIRK channel activation. Previous 
reports, however, typically indicate a negative role for RGS proteins in GIRK channel 
activity (Labouebe et al. 2007; Mutneja et al. 2005). Work presented elsewhere also 
makes loss of receptor function an unlikely explanation. Dr. Lydic’s laboratory has 
conducted GTPγS binding on a variety of receptors in Gnao1 
+/RGSi
 brains and found little 
change indicating both relatively normal receptor levels and G-protein coupling. Work by 
Lamberts et al. demonstrated enhanced activity of μ-opioid receptors within the PAG of 
Gnao1 
+/RGSi
 mice by assaying μ-opioid mediated suppression of calcium channels. Thus 
the molecular mechanism behind the loss of GIRK channel activity remains elusive but 
may involve trafficking of GIRK channels or signaling complex assembly. 
Based upon the discussion thus far we are left with one alternative hypothesis, 
despite prior in vitro data, Go may function in vivo to reduce GIRK activation. This 
actually fits with some prior in vivo work where Gnao1 
-/-
 mice demonstrated enhanced 
GIRK channel activity within the hippocampus (Greif et al. 2000) which they attributed 
to disruption of the normal Go /RGS coupling leaving another Gi/o family member to 
compensate that was not subject to RGS regulation by the RGS proteins present within 
the hippocampus. However, I think this is actually quite an unlikely explanation due to 
two major findings. One, relatively few RGS proteins demonstrate Go selectively and 
mRNA from several non-selective of RGS family members is abundant within the 
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hippocampus (Gold et al. 1997), Chapter 1). Additionally, I have now demonstrated that 
Gnao1
 +/RGSi
 mice have reduced GIRK channel activity which would not be expected 
based upon the rational presented in the Gnao1 
-/-
 paper. Therefore a possible explanation 
is that Go’s function in vivo may be to reduce GIRK signaling. The biochemical 
mechanism could be through a dominant negative effect whereby Go activation generates 
second messengers which serve to block other Gi/o family members from activating 
GIRK. Further experiments will be necessary to test this hypothesis. 
In summary we have identified that introduction of a Gnao1 RGSi allele in vivo 
selectively disrupts GIRK channel-dependent hypothermia pathways including those 
within the PAG. Further analysis centered upon the PAG in our mouse system should 
yield insights to the role of Go and RGS proteins in controlling the function of GIRK 
channels within this region. 
Materials and Methods 
Animal studies were performed in accordance with the Guide for the Care and 
Use of Laboratory Animals established by the National Institutes of Health; all 
experimental protocols were approved by the relevant University Committee on the Use 
and Care of Animals. Experiments were performed using male mice. All experimental 
mice were group-housed with unlimited access to food and water until experimentation. 
Lights were maintained on a 12-hour light/dark cycle with lights on at 5:00/6am 
depending on time of year. All experiments were conducted during the light phase. 
Generation of mice and genotyping 
The Gnao1 RGSi mutation was initially generated on the 129S1/SvImJ 
background which was used to produce RGSi mice on the B6129F1 and C57BL/6J 
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background as described in previous chapters. All mice had eartags inserted and tail 
biopsies taken prior to weaning. DNA was extracted from tails by an alkaline lysis 
method (Truett et al. 2000). The RGSi allele of Gnao1 was identified by PCR as 
described in chapter 2. Gnao1 
-/-
 mice were a generous gift of Dr. Mortenson and 
genotyped as previously reported (Duan et al. 2007). 
Hypothermia 
Experimenter was blinded to genotype. Mice were moved from group housing to 
individual cages with free access to food and water for 2 hours prior to experimentation. 
Starting at 30 minutes prior to drug administration baseline temperatures were recorded 
using a Tcat 2df controller rectal thermometer (Physitemp Clifton, NJ) which was placed 
at a 20 mm probe depth. This was repeated every 10 minutes until just prior to i.p. drug 
injection. The temperature taken just prior to drug injection was used as the baseline 
value (t=0). For single-dose studies, no further injections were administered and 
temperature was taken by rectal thermometer at the times indicated. For cumulative-dose 
response curves the first physiological read outs post-injection were taken at the time of 
peak effect in the respective single-dose vs time curve (i.e. 60 minutes for baclofen and 
20 minutes for 8-OH-DPAT). Following physiological read outs an i.p. injection of the 
relevant drug was administered and the same amount of time was allowed to pass prior to 
taking readings and injecting the next dose. 8-OH-DPAT (Sigma), morphine, and 
baclofen (Sigma) were dissolved in saline. Drugs were made as stocks and used over 
multiple days. Control and mutant mice were tested in equal numbers each day. 
Motor Impairment 
For those hypothermia experiments that also involved testing for motor 
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impairment, mice were trained on a rotarod set at 12 RPM in four sessions spaced 30 
minutes apart the day before the experiment. On the day of the experiment baseline 
performance was measured. Only mice that fell once or less during a 300 second test 
were used. Mice were then injected with baclofen, had their temperature taken, and then 
time on the rotarod was determined. Time spent clinging to the rotarod was excluded, 
similar to prior studies (Jacobson & Cryan 2005). 
Electrophysiology 
Mice were deeply anesthetized with isoflurane and the brains rapidly removed 
and placed in ice cold "cutting buffer" containing (in mM): 75 NaCl, 2.5 KCl, 0.1 CaCl2, 
6 MgSO4, 1.2 NaH2PO4, 25 NaHCO3, 2.5 D-dextrose, 50 sucrose. Coronal slices (~230 
µm) containing the periaqueductal gray area (PAG) were sliced in 95% O2 and 5% CO2 
oxygenated "cutting buffer”. Slices were incubated in warm (35 
0
C) oxygenated artificial 
cerebrospinal fluid (aCSF) containing (in mM): 126 NaCl, 2.5 KCl, 2.4 CaCl2, 1.2 
MgCl2, 1.2 NaH2PO4, 21.4 NaHCO3, 11.1 D-Dextrose, pH 7.4, and the osmolarity was 
adjusted to 300-310 mOsm. 
Whole cell patch clamp recordings were made from visually identified PAG 
neurons. Patch pipettes were pulled from borosilicate glass (WPI, Sarasota, FL) on a two-
stage puller (Narishige, Tokyo, Japan). Pipettes had a resistance of 2-4 Mohm and 
intracellular solutions contained (in mM): 138 potassium methylsulfate, 10 KCl, 0.3 
CaCl2, 1 MgCl2, 10 HEPES, 1 EGTA, 30 D-dextrose, 4 Mg-ATP, 1 Na-GTP; pH 7.3, 
280-290 mOsm. Whole cell series resistance was compensated ~80%. Neurons were held 
at -70 mV. Currents were collected at 2 kHz and digitized at 5 kHz using an Axopatch 
200B amplifier controlled by Axograph Data Acquisition software (AxographX, Sydney, 
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Australia). Recordings in which access resistance or capacitance changed by >15% 
during the experiment were excluded from data analysis. 
Quantitative Real Time PCR 
F1 males 8 weeks of age were decapitated and heads were placed in liquid 
nitrogen for 6 seconds to prevent mRNA degradation. Cortex and hippocampus dissected 
using a 30g coronal mouse brain matrix (Electron Microscopy Sciences) and 
homogenized in a bullet blender (Next Advance) per the manufacturer’s directions using 
homogenization buffer from an RNeasy Mini kit (QIAGEN, Valencia, CA). RNA was 
extracted using the RNeasy Mini kit following the manufacturer's instructions. Total 
RNA (1 μg) was reverse-transcribed after digestion with DNase using a TaqMan cDNA 
reverse transcription kit with random hexemer primers (Applied Biosystems, Foster City, 
CA). Quantitative real-time PCR was performed in 20-μl reactions containing 1 μl of the 
cDNA sample and 0.3 μM forward and reverse primers with the RT2 SYBR Green qPCR 
Master Mix (SABiosciences, Frederick, MD). 
Statistics 
Data were analyzed using GraphPad Prism 5.0 (GraphPad; LaJolla, CA). All data are 
reported as mean ± SEM. Two-way ANOVA was employed in the analysis of thermal 
and motor impairment figures. Student's t-test and ANOVA were used where appropriate 
for electrophysiology. Two-tailed p values less than 0.05 were considered significant.
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Chapter 5  
Synthesis 
This thesis elucidated a role for Go in modulating kindling susceptibility. One 
method was a pharmacological approach assessing altered receptor signaling in a novel 
Go gain-of-function mouse model. The second was a genetic approach to identify unique 
modifiers of the pro-seizure phenotype found in mutant mice. The work presented in this 
thesis has further highlighted the critical role for Go signaling in models of epilepsy and 
modulation of specific outcomes in GPCR signaling. Future work building upon this 
foundation will be of critical importance in the development of therapies for the recently 
recognized role of mutations within GNAO1 in epileptic encephalopathy (Nakamura et al. 
2013). 
Unique role for Go in kindling susceptibility 
A variety of laboratories has previously identified activation of Gi/o-coupled 
GPCRs as protective from seizures (Grecksch et al. 2004; Pericic et al. 2005). However it 
remained to be determined which inhibitory G protein was involved in this process. 
Several labs generated Go null mice and noted no overt seizure phenotype (Duan et al. 
2007; Jiang et al. 1998). However my thesis suggests Go as a key player in modifying 
CNS excitability. This further supports the observation of one other laboratory that did 
report spontaneous seizures in Go null mice (Valenzuela et al. 1997). 
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The prior literature discussed above provided a simplistic understanding of Go 
where Go activation was considered to be protective from seizures. However recent 
research, including in my own thesis, has highlighted the importance of finely tuning the 
level of Go activity. Nakamura et al. identified a mutation that is highly analogous to our 
own RGSi mutation in patients with epileptic encephalopathy (Nakamura et al. 2013). In 
support of this mutation likely being a gain-of-function, my thesis demonstrates, for the 
first time, that enhanced Go signaling in a rodent model enhances susceptibility to 
kindling and promotes the development of spontaneous electrical disturbances within the 
brain. While other mutations found by Nakamura et al. were predicted to be loss-of-
function, this does not match my rodent data whereby mice with a 50% reduction in Go 
protein levels do not display sensitization to kindling (Figure A.2). Thus I would 
postulate that these mutations, might in fact, act as dominant negatives. 
Prior work in cell culture experiments has implicated a role for Go in neuronal 
development and migration, which is suggestive of a possible mechanism at play in the 
enhanced kindling susceptibility. Yet prior studies in Go null mice were unable to detect 
morphological abnormalities within the CNS (Valenzuela et al. 1997). Here, for the first 
time, I report anatomical abnormalities as a reduction in spine density due to enhanced Go 
signaling (Figure A.4). Though it remains to be determined if the changes are a primary 
result of the mutation or a secondary defect due to IEDs. 
Mouse models studying Go effectors implicate reduced GIRK activity as a likely 
mechanism of Gnao1 
+/RGSi
 enhancement of kindling. Historically within the literature 
two of the major targets of Go activation are N-type calcium channels and GIRK 





however, is unlikely to result in seizures based upon animal model data. N-type calcium 
channel null mice are viable, and despite three different independently generated lines no 
mention of altered seizure susceptibility is mentioned (Hatakeyama et al. 2001; Kim et 
al. 2001; Saegusa et al. 2001). Girk2 
-/-
 mice however display spontaneous seizures and 
premature death like Gnao1 
+/RGSi
 mice (Signorini et al. 1997). While prior in vitro 
literature proposed a positive role for Go in GIRK channel activation (Fernandez-
Fernandez et al. 2001), Chapter 4 of my thesis demonstrates a negative role for Go 
activity in GIRK channel activity. This conclusion is further supported by prior in vivo 
work which found enhanced GIRK activity in Gnao1 
-/-
 mice (Greif et al. 2000). One 
possible mechanism behind Go’s unexpected suppression of GIRK channel activity is that 
the specific βγ subunits that Go releases bind, but have low efficacy to activate GIRK 
channels. Thus βγ from Go may act in a dominant-negative fashion. Future studies in 
transfected primary neurons will be required to test this hypothesis. An additional way to 
test the significance of reduced GIRK channel activity in the enhanced kindling 
phenotype would be to see if administration of the newly discovered direct GIRK channel 
activator, ML297, ameliorates the phenotype (Kaufmann et al. 2013). 
Identification of a novel modifier of epilepsy with relevance to human patients 
Genetic modifiers which influence the progression of spontaneous seizures in 
mouse models of epilepsy have been identified (Bergren et al. 2009). However the model 
systems employed typical utilize ion channel mutations. It remains unknown if 
therapeutics leveraging these modifiers will improve treatment for epilepsies of other 
origins. Significantly, the novel work of my thesis indicates another modifier on mouse 
Chr17 could provide useful insights in the treatment of idiopathic epilepsies that depend 
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on altered GPCR signaling. This is particularly relevant in light of new data suggesting 
de novo mutations in GNAO1 can contribute to epilepsy (Nakamura et al. 2013). 
Understanding sudden unexpected death in epilepsy (SUDEP) has proved quite 
challenging with few known risk factors (Surges & Sander 2012). One animal model 
involving a loss of Kv1.1 demonstrated that mutations increasing parasympathetic tone 
can be a risk factor (Glasscock et al. 2010). Modifiers protective from this phenotype 
have yet to be identified. Interestingly, our Gnao1
+/RGSi
 mice are also likely to have 
enhanced parasympathetic signaling as Go plays a major role in these signaling pathways 
(Duan et al. 2007);(Valenzuela et al. 1997). Therefore Mogs1 should also be considered 
as a potential modifier of SUDEP. To support this theory it will be of interest to see if 
Mogs1 is able to reduce the incidence of SUDEP in mice lacking Kv1.1. 
 Future directions 
Model system development 
The model used in my thesis has a major limitation. Temporal or spacial 
dissection of Go signaling is not possible due to the global nature of the mutation. This is 
particularly significant in light of the IED activity found in the B6.129 Gnao1 
+/RGSi
 mice. 
Further dissecting the molecular mechanisms of any phenotype will prove challenging as 
the phenotype may be secondary to the IED activity. Time course experiments to find 
primary defects will be required to determine the origin of the IED activity. However to 
study the role of Go in other neurotransmitter systems within the mature brain alternative 
models will be required to overcome this limitation. 
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To avoid complications due to IED activity Gnao1 
+/RGSi
 mice could be studied on 
a different genetic background. The two alternative backgrounds currently available 
include B6x129 F1 and 129S1/SvImJ. Mutant F1 mice may not display spontaneous 
IEDs as, in contrast to their B6 counterparts, they do not experience spontaneous death. 
Normal baseline EEG activity may, however, be an unrealistic assumption because 
mutant F1 mice parallel their B6 counterparts in rapid PTZ kindling (Figure A.1). 
Studying mutants on the 129 background is a second option. The fact that they kindle at 
the same rate as control makes their having normal baseline EEG activity more likely. 
However the 129 strain has several disadvantages including poor breeding and minimal 
locomotion (Labs 1998). The minimal locomotion presents a problem due to the 
behavioral nature of many assays. Thus studying the mutation on the 129 genetic 
background may not prove fruitful. 
An alternate approach would be to develop a mouse model that could be 
temporally and spacially controlled. This could be accomplished through the 
development of a conditional knock-in. However, based upon the Neubig lab’s 
experience in developing the Gi2 conditional knock-in, the use of a minigene can 
dramatically reduce protein expression. Reduced protein expression was also a 
complicating factor for one researcher who attempted to create a conditional Gnao1 
+/RGSi
 
mouse (personal communcation). However, the cause of reduced protein expression can 
not be conclusively tied to the mutation as the neo cassette was not removed, which can 
also reduce protein expression. 
One approach to overcome the limitations of a conditional knock-in is the use of a 
transgenic BAC containing a Cre inducible Gnao1 RGSi allele. Gain-of-function 
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mutations typically lead to dramatic phenotypes as highlighted in the introductory 
chapter. Thus even if only 1/3 of the Go is from the RGSi allele it should be sufficient for 
experimental purposes. 
Future research areas 
The mechanism of IED development should be further pursued as IEDs are 
recognized as a clinically significant problem leading to deficits in cognitive function 
(Jaseja 2007) (Pressler et al. 2005). Despite their significance, the effectiveness of current 
medications in reducing IED frequency is under debate (D'Antuono et al. 2010; Pressler 
et al. 2005); (Stodieck et al. 2001). Despite the purported benefits of suppressing IEDs, 
evidence has also been presented for a protective role of IEDs to reduce frequency of 
seizures (Avoli 2001). Understanding the development of IEDs in Gnao1 
+/RGSi
 mice 
should yield insights into how best to suppress IEDs and the long term consequences of 
doing so. 
Understanding excitatory signaling within the piriform cortex and hippocampus 
of Gnao1 
+/RGSi
 mice is likely a key step in understanding the mechanism of IED 
development. This is a result of several lines of data. IEDs occur within the piriform 
cortex early in the kindling process and only later propagate to the hippocampus (de 
Curtis et al. 1999). B6.129 Gnao1 
+/RGSi
 mice kindle more quickly potentially indicating 
alterations in the propagation of IEDs within these mice. Yukun Yuan in our lab has 
generated preliminary data that spontaneous inhibitory post synaptic events are reduced 
both in frequency and amplitude (Figure A.3). This data could support the hypothesis that 
suppression of GABA release in Gnao1 
+/RGSi
 mice contributes to IED development. 
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 There are other alternative explanations for the changes observed by Yukun, 
including either death of inhibitory neurons, which commonly occurs in epileptic brains 
(Buckmaster & Jongen-Relo 1999), or a lower density of inhibitory synapses. The 
viability of interneurons in the adult brains should be further explored. A decrease in 
inhibitory cell number would support the hypothesis that Go 
+/RGSi
 mice experience 
spontaneous seizures, which is still under debate. If no changes were observed it would 
rule out a decrease in inhibitory neurons as an explanation of Yukun’s data. 
Future experimentation should also focus on cardiac function in Gnao1 
+/RGSi
 
mice. Go, beyond being expressed in the brain, is also present in the heart. Here it is 
responsible for controlling the bradycardia response to muscarinic agonists (Duan et al. 
2007). Thus I would hypothesize that Gnao1 
+/RGSi
 mice should have enhanced 
muscarinic induced bradycardia. This could have two significant implications for the 
findings of my thesis. First, cardiac dysfunction may precipitate seizures through 
hypoxia-induced neuronal cell death. Secondly, the strain-dependent spontaneous death 
may be a model for sudden unexpected death in epilepsy (SUDEP). 10-15% of those who 
experience SUDEP have long QT intervals, indicating cardiac dysfunction (Surges & 
Sander 2012). Further, one proposed mechanism of SUDEP is post-ictal bradycardia or 
hypoventilation (Surges & Sander 2012). Testing both a brain and cardiac specific Gnao1 
+/RGSi
 mouse line in kindling and spontaneous death would prove critical to ruling out the 
role of cardiac dysfunction in Gnao1 
+/RGSi
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Figure A.1 F1 Gnao1 +/RGSi mice kindle faster than control 
Female F1 mice were subjected to the kindling protocol 
in Chapter 2. Mutant mice kindle faster than control. 




























Figure A.2 A 50% reduction in Go protein levels does not alter kindling 
Female Gnao1
 +/-
 mice on the B6 background were subjected to 
kindling following the protocol in Chapter 2. Loss of protein 





Figure A.3 Gnao1 +/RGSi mice have lower amplitude and less frequent sIPSC 
Dr Yuan tested adult B6 mice for changes in inhibitory signaling. These findings 
are indicative of mutant mice having less inhibitory signaling. 
 
Figure A.4 Gnao1 +/RGSi mice have a lower 
CA1 spine density by 4 weeks of age 
Gnao1 
+/RGSi
 mice were bred with GFPm 
mice. At 4 weeks of age brains were 
harvested and spine density of CA1 
pyramidal cells was calculated. Mutant 
mice have a lower spine density at several 




Figure A.5 Gnai2 +/RGSi mutant mice kindle at a rate comparable to control 
The RGSi mutation in the Gi2 protein has no impact on the rate of kindling 
even on the B6 background. 
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Figure A.6 Gnai2 +/G184S mice display responses to baclofen similar to that of control 
A) 6 mg/kg hypothermia response B) 10 mg/kg hypothermia response C) 6mg/kg motor impairment D) 
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